Method for treatment of diarrhea-predominant irritable bowel syndrome

ABSTRACT

The present invention provides methods for treating diarrhea-predominant irritable bowel syndrome comprising administering to a patient in need thereof, an inhibitor of chloride-ion transport in an amount sufficient to treat diarrhea-predominant irritable bowel syndrome (d-IBS). Treatment of d-IBS includes the treatment of the diarrhea component of d-IBS as well as the pain, abdominal discomfort and other symptoms associated with d-IBS. In one embodiment, the inhibitor of chloride-ion transport is crofelemer.

RELATED APPLICATIONS

This application is a continuation application of U.S. patentapplication Ser. No. 13/304,604, filed Nov. 25, 2011, which is acontinuation application of U.S. patent application Ser. No. 11/510,152,filed Aug. 24, 2006, which claims priority to U.S. ProvisionalApplication No. 60/797,074, filed May 1, 2006. The entire contents ofeach of the aforementioned applications are incorporated herein byreference in their entirety.

BACKGROUND OF THE INVENTION

Irritable bowel syndrome (IBS) is a common functional disorder of thebowel that has a pronounced effect on quality of life. A definingcharacteristic of IBS is abdominal discomfort or pain. The Rome IIDiagnostic Criteria (a system for diagnosing functional gastrointestinaldisorders based on symptoms) for IBS is as follows: at least 12 weeks ormore, which need not be consecutive, in the preceding 12 months ofabdominal discomfort or pain that is accompanied by at least two of thefollowing features: (1) it is relieved with defecation, and/or (2) onsetis associated with a change in frequency of stool, and/or (3) onset isassociated with a change in form (appearance) of stool.

Other symptoms that support the diagnosis of IBS include pain; abnormalstool passage (straining, urgency, or feeling of incomplete evacuation);passage of mucus; and bloating or feeling of abdominal distension.Patients can be sub-divided by their underlying bowel habits: (i)diarrhea-predominate IBS, (ii) constipation-predominate IBS, and (ii)constipation alternating with diarrhea (alternating IBS).

The pathophysiology of IBS is poorly understood despite the fact thatabout a quarter of the population in the UK may exhibit the symptoms,and approximately 15 percent of U.S. adults report symptoms that areconsistent with the diagnosis of IBS. It is estimated that only 25percent of persons with IBS seek medical care. In addition, patientsdiagnosed with IBS are at increased risk for other, non-gastrointestinalfunctional disorders such as fibromyalgia and interstitial cystitis.

IBS is the most common diagnosis made by gastroenterologists in theU.S., and accounts for 12 percent of visits to primary care providers.Approximately $8 billion in direct medical costs and $25 billion inindirect costs are spent annually in the U.S. for diagnosing andtreating IBS. Thus, IBS accounts for a large proportion of annualhealthcare costs in the U.S.

Primary treatment of IBS involves counseling and dietary modification.Drug therapy is considered to be beneficial if directed at individualsymptoms. For diarrhea predominant cases, antidiarrheal drugs such asloperamide can be used, which treat diarrhea, but not abdominal pain.Since abdominal pain is one of the defining characteristic of IBS,anti-diarrheal drugs do not adequately treat IBS (Jailwala et al., 2000,Ann Intern Med. 2000; 133:136-147; Cremonini et al., 2004, Minerva Med95:427-441). For constipation predominant cases, ispaghula is often usedto increase dietary fiber. Where patients have pain and distension aspredominant symptoms, anti-spasmolytics are commonly used. Mebeverineand peppermint oil are often used in such cases. Other agents that havebeen tried for treating IBS include beta-blockers, naloxone,ondansetron, calcium channel blockers, simethicone, leuprorelin,octreotide and cholecystokinin antagonists with variable results(Martindale, The Extra Pharmacopoeia, 31st Edition (1996) p. 1197).

Alosetron hydrochloride, Lotronex® (GlaxoSmithKline, Research TrianglePark, N.C.), a selective 5-hydroxytryptamine 3 (5-HT₃) antagonist iscurrently the only drug approved for treating females with severediarrhea-predominant irritable bowel syndrome (d-IBS). Due to safetyconcerns, including ischemic colitis and severe, life threateningconstipation, even this one drug is approved for use only in women withsevere d-IBS. Although there are other drugs for the treatment ofdiarrhea (e.g. loperamide, diphenoxylate), such drugs do not address themultiple symptoms of d-IBS including pain and abdominal discomfort and,thus, are not long-term options. (See Wood, 2003, AJJ. NEMJ 349:2136-2146). There is a need for improved therapeutics for the treatmentof d-IBS that address the multiple symptoms of d-IBS including pain andabdominal discomfort.

U.S. Pat. Nos. 5,211,944 and 5,494,661 to Tempesta disclose the use of aproanthocyanidin polymeric composition isolated from Croton spp. orCalophyllum spp. for the treatment of viral infections. Rozhon et al.,U.S. Patent Publication No. 2005/0019389, disclose the use of aproanthocyanidin polymeric composition isolated from Croton spp. orCalophyllum spp. for the treatment of secretory or traveler's diarrhea.Di Cesare et al., 2002, Am J Gastroenterol 10:2585-2588 disclose aclinical trial of crofelemer as a treatment for traveler's diarrheacompared to placebo. Dosages used in this study were 500 mg/day (125four times a day); 1000 mg/day (250 mg four times a day); and 2000mg/day (500 mg four times a day) for two days. The study showed that thecomposition was useful for the amelioration of stool frequency andgastrointestinal symptoms in patients with traveler's diarrhea.

Citation or identification of any reference in this section or any othersection of this application shall not be construed as an admission thatsuch reference is available as prior art for the present application.

SUMMARY OF THE INVENTION

The present invention relates to methods for treating at least onesymptom of diarrhea-predominant irritable bowel syndrome (d-IBS) byadministering a molecule that inhibits secretion of chloride ions from acell (inhibitor molecule). Exemplary inhibitor molecules are those thatinhibit secretion of chloride ions through the cystic fibrosistransmembrane conductance regulator chloride-ion channel (CFTR). Otherexemplary inhibitor molecules include potassium ion channel openers.Exemplary symptoms of d-IBS include pain, abdominal discomfort,diarrhea, abnormal stool frequency, abnormal stool consistency and thepresence of urgency. Thus, in one embodiment, the invention provides amethod for the treatment of one or more symptoms of d-IBS comprisingadministering to a patient in need of such treatment, an amount of amolecule that inhibits secretion of chloride ions from a cell (inhibitormolecule) effective to treat the one or more symptoms of d-IBS. Inpreferred embodiments, the dosage of the inhibitor molecule isbioequivalent to orally administered enteric coated crofelemer at adosage of about 50 mg per day to about 750 mg per day. In oneembodiment, bioequivalency is a sufficient dose of an inhibitor moleculeto produce a similar therapeutic effect as seen with another inhibitormolecule at a particular dosage, e.g., crofelemer at a dosage of about50 mg per day to about 750 mg per day. In another embodiment,bioequivalency is as defined by, or is as determined in accordance withmethods approved by, the U.S. Food and Drug Administration. In aparticular embodiment, the inhibitor molecule is co-administered with acompound that inhibits COX-2, and preferably selectively inhibits COX-2over COX-1, which compound is preferably not systemically absorbed. Suchcompounds include 5-ASA, sulfasalazine, mesalamine, APAZA, as well asother commercially available COX-2 inhibitors such as celecoxib androfecoxib.

In a particular embodiment, the present invention is directed to amethod of treating pain and diarrhea associated with d-IBS comprisingadministering to a patient in need of such treatment, an amount of amolecule that inhibits secretion of chloride ions from a cell (inhibitormolecule) effective to treat pain and diarrhea associated with d-IBS. Inanother embodiment, the present invention is directed to a method oftreating abdominal discomfort and diarrhea associated with d-IBScomprising administering to a patient in need of such treatment, anamount of a molecule that inhibits secretion of chloride ions from acell (inhibitor molecule) effective to treat abdominal discomfort anddiarrhea associated with d-IBS. In another particular embodiment, thepresent invention is directed to a method of treating pain associatedwith d-IBS comprising administering to a patient in need of suchtreatment, an amount of a molecule that inhibits secretion of chlorideions from a cell (inhibitor molecule) effective to treat pain associatedwith d-IBS. In another embodiment, the present invention is directed toa method of treating abdominal discomfort associated with d-IBScomprising administering to a patient in need of such treatment, anamount of a molecule that inhibits secretion of chloride ions from acell (inhibitor molecule) effective to treat abdominal discomfortassociated with d-IBS. Optionally, analgesic or anti-inflammatory agentscan be co-administered with the inhibitor molecule. In particular, theagent is formulated or is modified such that it is not systemicallyabsorbed.

In another embodiment, the present invention is directed to a method oftreating diarrhea associated with d-IBS comprising administering to apatient in need of such treatment, an amount of a molecule that inhibitssecretion of chloride ions from a cell (inhibitor molecule) effective totreat the diarrhea associated with d-IBS, with the proviso that theinhibitor molecule is not a polymeric proanthocyanidin compositionisolated from Croton spp. or Calophyllum spp. or that the inhibitormolecule is not crofelemer. In yet another embodiment, the presentinvention is directed to a method of treating abnormal stool frequency,abnormal stool consistency or presence of urgency associated with d-IBScomprising administering to a patient in need of such treatment, anamount of a molecule that inhibits secretion of chloride ions from acell (inhibitor molecule) effective to treat the abnormal stoolfrequency, abnormal stool consistency or presence of urgency associatedwith d-IBS, with the proviso that the inhibitor molecule is not apolymeric proanthocyanidin composition isolated from Croton spp. orCalophyllum spp. or that the inhibitor molecule is not crofelemer.

In another embodiment, the present invention is directed to a method oftreating diarrhea associated with d-IBS comprising orally administeringto a patient in need of such treatment, an amount ofenterically-protected crofelemer (CAS 148465-45-6) effective to treatthe diarrhea associated with d-IBS, in which said amount is betweenabout 50 mg per day and about 750 mg per day. In yet another embodiment,the present invention is directed to a method of treating abnormal stoolfrequency, abnormal stool consistency or presence of urgency associatedwith d-IBS comprising orally administering to a patient in need of suchtreatment, an amount of enterically-protected crofelemer effective totreat the abnormal stool frequency, abnormal stool consistency orpresence of urgency associated with d-IBS, in which said amount isbetween about 50 mg per day and about 750 mg per day. In certainembodiments where crofelemer is otherwise formulated, for example, in acontrolled release formulation (not enterically protected), the dosageof crofelemer administered is bioequivalent to a dosage of about 50 mgper day to about 750 mg per day of orally administeredenterically-protected crofelemer.

In another embodiment, the present invention is directed to a method oftreating diarrhea associated with d-IBS comprising administering to apatient in need of such treatment, an amount of a polymericproanthocyanidin composition isolated from Croton spp. or Calophyllumspp. effective to treat the diarrhea associated with d-IBS, in whichsaid amount is bioequivalent to an orally administered dose of about 50mg per day to about 750 mg per day of crofelemer. In yet anotherembodiment, the present invention is directed to a method of treatingabnormal stool frequency, abnormal stool consistency or presence ofurgency associated with d-IBS comprising administering to a patient inneed of such treatment, an amount of a polymeric proanthocyanidincomposition isolated from Croton spp. or Calophyllum spp. effective totreat the abnormal stool frequency, abnormal stool consistency orpresence of urgency associated with d-IBS, in which said amount isbioequivalent to an orally administered dose of about 50 mg per day toabout 750 mg per day of crofelemer.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 is a graph illustrating the Effect of Crofelemer 125 mg bid onStool Frequency in Females.

FIG. 2 is a graph illustrating the Effect of Crofelemer 125 mg bid onUrgency in Females.

FIG. 3 is a graph illustrating the Effects of Crofelemer on AdequateRelief of IBS Symptoms in Females.

FIG. 4 is a graph illustrating the Effect of Crofelemer on Pain Score inFemales.

FIG. 5 is a graph illustrating the Effect of Crofelemer on Percent ofPain Free Days in Females.

FIG. 6 is a graph illustrating the Effect of Crofelemer on Pain Score inFemales.

FIGS. 7A-7H show exemplary CFTR inhibitor molecules useful in themethods of the present invention. FIG. 7A is3-[(3-trifluoromethyl)phenyl]-5-[(3-carboxyphenyl)methylene]-2-thioxo-4-thiazolidinone;FIGS. 7B and 7F are glycine hydrazides; FIGS. 7C, 7D, 7E, 7G and 7H aremalonic acid hydrazides. As discussed, infra, these molecules can beoptionally pegylated to make them non-absorbable in the intestines.

FIG. 8 is a schematic of Tablet Core Manufacturing Process.

FIG. 9 is a schematic of Tablet-Core Spray-Coating Process.

FIG. 10 is a schematic of Over-Encapsulation of Enteric-Coated Tables.

DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to methods for treating at least onesymptom of diarrhea-predominant irritable bowel syndrome (d-IBS) byadministering a molecule that inhibits secretion of chloride ions from acell (inhibitor molecule). Exemplary inhibitor molecules are those thatinhibit secretion of chloride ions through the cystic fibrosistransmembrane conductance regulator chloride-ion channel (CFTR). Otherexemplary inhibitor molecules include potassium ion channel openers.Exemplary symptoms of d-IBS include pain, abdominal discomfort,diarrhea, abnormal stool frequency, abnormal stool consistency and thepresence of urgency. Thus, in one embodiment, the invention provides amethod for the treatment of one or more symptoms of d-IBS comprisingadministering to a patient in need of such treatment, an amount of amolecule that inhibits secretion of chloride ions from a cell (inhibitormolecule) effective to treat the one or more symptoms of d-IBS.

The present invention is based, in part, on the discovery that polymericproanthocyanidin compositions isolated from Croton spp. or Calophyllumspp., for example, crofelemer, alleviate pain and abdominal discomfortassociated with d-IBS. Further, the present invention is based, in part,on the discovery that chloride ion transport in epithelial cells, forexample, through the cystic fibrosis transmembrane conductance regulatorchloride-ion channel (CFTR), is involved not only in secretory (acute)diarrhea but also is unexpectedly involved in the etiology ofdiarrhea-predominant irritable bowel syndrome (d-IBS). Additionally, thepresent invention is based, in part, on the discovery that polymericproanthocyanidin compositions isolated from Croton spp. or Calophyllumspp., for example, crofelemer, alleviate the diarrheal symptoms ofd-IBS, such as abnormal stool frequency, abnormal stool consistency andpresence of urgency, at dosages significantly less than those previouslyused for treating secretory diarrhea. For example, dosages previouslytaught to be effective in treating secretory diarrhea comprised 5,500 mgof orally administered enterically-protected crofelemer over two days,whereas exemplary dosages in the present invention comprise betweenabout 50 mg and about 750 mg per day of orally administeredenterically-protected crofelemer.

Chloride ion transport can be inhibited by a number of mechanisms. Forexample, chloride ion secretion can be inhibited by affecting thefunction of the cystic fibrosis transmembrane conductance regulatorchloride ion channel (CFTR) such that chloride ion transport isinhibited. Chloride ion secretion can also be inhibited by openingpotassium ion channels in a cell. Chloride-ion secretion can also beinhibited by blocking up-regulation of cAMP.

The cystic fibrosis transmembrane conductance regulator chloride ionchannel (CFTR) is a 1480 amino acid protein which has been associatedwith the expression of chloride conductance in a variety of eukaryoticcell types. See Rommens et al., 1989, Science 245:1059; Riorden et al.,1989, Science 245:1066; Kerem et al., 1989, Science 245:1073; Drumm etal., 1991, Cell 64:681; Kartner et al., 1991, Cell 64:681; Gregory etal., 1990, Nature 347:382; Rich et al., 1990, Nature 347:358; andRommens et al., 1991, Proc. Nat. Acad. Sci. USA 88:7500. Defects in CFTRdestroy or reduce the ability of epithelial cells in the airways, sweatglands, pancreas and other tissues to secret chloride ions in responseto cAMP-mediated agonists and impair activation of apical membranechannels by cAMP-dependent protein kinase A (PKA). See Frizell et al.,1987, Trends Neurosci 10:190; Welsh, 1990, FASEB J. 4:2718.

The nucleotide and amino acid sequences of CFTR have been cloned(Riordan et al., 1989, Science 245:1066-1073 and are accessible inGenBank under Accession No. M28668 and in SwissProt under Accession No.P13569, respectively.

Inhibitor molecules useful in the methods of the present inventioninclude any molecule that inhibits chloride-ion secretion, e.g., byinhibiting the function of CFTR or by opening potassium ion channels orby inhibiting up-regulation of cAMP, thus preventing the opening ofchloride ion channels. In particular embodiments, the inhibitormolecules of the invention include small molecules that are formulatedas to be immobilized onto polymers to limit systemic absorption, as wellas isolated naturally occurring CFTR inhibitors, potassium-ion channelopeners, cAMP blockers/inhibitors and synthetic or semisynthetic formsthereof. Analogs, derivatives and modified forms of the inhibitors ofthe invention are also contemplated.

Many molecules are known in the art that are useful in the methods ofthe present invention. For example, exemplary molecule that inhibit CFTRfunction include sparteine (U.S. Pat. No. 5,100,647); thiazolidinonecompounds such as those described, for example, in U.S. PatentApplication Publication Nos. 2004-0063695 and 2004-0235800, such as2-thioxo-4-thiazolidinone compounds and3-[(3-trifluoromethy)phenyl]-5-[(3-carboxyphenyl)methylene]-2-thioxo-4-thiazolidinone, which is described in Thiagarjahet al., 2004, Gastroenterology 126:511-519 (see FIG. 7) or other2-thioxo-4-thiazolidinone analogs and derivatives thereof;N-(2-naphthalenyl)-[(3,5-dibromo-2,4-dihydroxyphenyl)methylene]glycinehydrazide or other glycine hydrazide analogues or derivatives thereof(see FIG. 7); malonic acid dihydrazides or analogues or derivativesthereof (see FIG. 7); sulfonylureas such as tolbutamide, glibenclamideand related analogs as described, for example, in U.S. Pat. No.5,234,922; fluorescein or a derivative thereof such as those described,for example, in U.S. Patent Application Publication No. 2004-0092578;and nonhydrolyzable analogs of cAMP or cGMP that inhibit, rather thanactivate, CFTR function such as 8-bromo-cAMP, 8-(4-chlorophenylthio)(CPT)-cAMP and 8-bromo-cGMP, CPT-cGMP.

Additional exemplary inhibitor molecules include, but are not limitedto: verapamil; nifedipine; diltiazem; disulfonic stilbene compounds;arylaminobenzoates or analogs or derivatives thereof such asdiphenylamine-2-carboxylate (DPC) or5-nitro-2(3-phenylpropylamino)benzoate (NPPB) or anthracene-9-carboxylicacid (9-AC); flufenamic acid (FFA); 9-(tetrahydro-2-furyl) adenine(SQ22536); 2′,5′-dideoxyadenosine (DDA); loperamide; racecadotril;lidamidine hydrochloride; lonidamine; vanadate; bumetanide; pp2a; PP1;PP2B; bismuth subsalicylate; diphenoxylate hydrochloride; and sparteine.Additional discussion and information regarding the above compounds maybe found in Fedorak et al., 1987, Digestive Disease and Sciences32(2):195-205; Farthing, 2004, Expert Opin. Investig. Drugs13(7):777-785; Suzuki et al., 2003, J. Physiol. 546(3):751-763; Sullivanet al., 1996, Kidney International 49:1586-1591; Galietta et al., 2004,Curr. Opin. Pharmacol. 4:497-503. Additional discussion and examples ofchloride channel inhibitors are disclosed in Greger, 1990, Methods inEnzymology 191:793-810. All of the foregoing patent and non-patentreferences are incorporated by reference herein in their entireties.

Inhibitor molecules of the invention also include potassium-ion channelopeners such as diazoxide, lemakalim and minoxidil sulfate, as well asrelated analogs such as those described for example, in U.S. Pat. No.5,234,922.

Additional exemplary inhibitor molecules include naturally occurringCFTR inhibitors and synthetic or semisynthetic forms thereof include,for example, flavonoids including, but not limited to cocoa-relatedflavonoids isolated from cocoa beans as described in Schuier et al.,2005, J. Nutr. 135:2320-2325; fatty acids including but not limited to,arachidonic acid, linoleic acid, oleic acid, elaidic acid, palmiticacid, myristic acid, lysophosphatidic acid, and niflumic acid;flavonols; polyphenols; proanthocyanidins; oligomeric proanthocyanidins(OPCs); procyanidolic oligomers (PCOs); tannins; condensed tannins;leukocynanidins; anthocyanidins; procyanidins (e.g., B1-B5 and C1-C2);cyanidins; prodelphinidins; delphinidins; catechins; epicatechins;gallocatechins; epigallocatechins; epigallocatechin gallate; epicatechingallate; catechin gallate; gallocatechin gallate; quercetin;sesquiterpenes; diterpenes; terpenes and terpenoid derivatives;alkaloids; saponins; morin; luteolin; baicalein; and apigenin; andoligomers, polymers, copolymers and derivatives of any of the foregoing.

In one preferred embodiment, the inhibitor molecule is aproanthocyanidin polymer composition. In another embodiment, theproanthocyanidin polymer composition is an aqueous solubleproanthocyanidin polymer composition. In another preferred embodiment,the inhibitor molecules of the present invention are not systemicallyabsorbed or are modified not to be systemically absorbed whenadministered orally.

Proanthocyanidins are a group of condensed tannins. Tannins are found ina wide variety of plants and are classified as either hydrolyzable orcondensed. Many plants used in traditional medicine as treatment orprophylaxis for diarrhea have been found to contain tannins andproanthocyanidins in particular (see, e.g., Yoshida et al., 1993,Phytochemistry 32:1033; Yoshida et al., 1992, Chem. Pharm. Bull.,40:1997; Tamaka et al., 1992, Chem. Pharm. Bull. 40:2092). Crudeextracts from medicinal plants, for example, Pycanthus angolenis andBaphia nitida, have been shown to have antidiarrheal qualities in animaltests (Onwukaeme and Anuforo, 1993, Discovery and Innovation, 5:317;Onwukaeme and Lot, 1991, Phytotherapy Res., 5:254). Crude extracts whichcontain tannins, in particular extracts from carob pods and sweetchestnut wood, have been proposed as treatments or prophylactics fordiarrhea (U.S. Pat. No. 5,043,160; European Patent No. 481,396).

Proanthocyanidins are comprised of at least two or more monomer unitsthat may be of the same or different monomeric structure. The monomerunits (generally termed “leucoanthocyanidin”) are generally monomericflavonoids which include catechins, epicatechins, gallocatechins,galloepicatechins, flavanols, flavonols, and flavan-3,4-diols,leucocyanidins and anthocyanidins. Therefore, the polymer chains arebased on different structural units, which create a wide variation ofpolymeric proanthocyanidins and a large number of possible isomers(Hemingway et al., 1982, J.C.S. Perkin, 1:1217). Larger polymers of theflavonoid 3-ol units are predominant in most plants, and are found withaverage molecular weights above 2,000 daltons, containing 6 or moreunits (Newman et al., 1987, Mag. Res. Chem., 25:118).

Proanthocyanidin polymers are found in a wide variety of plants,particularly those with a woody habit of growth (e.g., Croton spp. andCalophyllum spp.). A number of different Croton tree species, includingCroton sakutaris, Croton gossypifolius, Croton palanostima, Crotonlechleri, Croton erythrochilus and Croton draconoides, found in SouthAmerica, produce a red viscous latex sap called Sangre de Drago or“Dragon's Blood”. This red, viscous latex is widely known for itsmedicinal properties. For example, U.S. Pat. No. 5,211,944 firstdescribed the isolation of an aqueous soluble proanthocyanidin polymercomposition from Croton spp. and the use of the composition as anantiviral agent (See also Ubillas et al., 1994, Phytomedicine, 1:77).The proanthocyanidin polymer composition was shown to have antiviralactivity against a variety of viruses including, respiratory syncytial,influenza, parainfluenza and herpes viruses. U.S. Pat. No. 5,211,944also discloses the isolation of an aqueous soluble proanthocyanidinpolymer composition from Calophyllum inophylum and the use of thiscomposition as an antiviral agent.

Exemplary proanthocyanidin polymer compositions useful in the presentinvention are preferably isolated from a Croton spp. or Calophyllum sppby any method known in the art. For example, the proanthocyanidinpolymer composition may be isolated from a Croton spp. or Calophyllumspp. by the method disclosed in Example 2, infra, or disclosed in U.S.Pat. No. 5,211,944 or in Ubillas et al., 1994, Phytomedicine 1: 77-106.

In one preferred embodiment, a proanthocyanidin polymer composition ofthe invention is crofelemer. Crofelemer (CAS 148465-45-6) is anoligomeric proanthocyanidin of varying chain lengths derived from theDragon's Blood of Croton lecheri of the family Euphorbiaceae. Crofelemerhas an average molecular weight of approximately 1900 daltons toapproximately 2700 daltons. The monomers comprising crofelemer comprisecatechin, epicatechin, gallocatechin, and epigallocatechin. The chainlength of crofelemer ranges from about 3 to about 30 units with anaverage chain length of about 8 units. The structure of crofelemer isshown below.

Wherein the average n=6.

Another illustrative method for isolating crofelemer can be found inU.S. Patent Publication No. 2005/0019389, the contents of which areexpressly incorporated herein.

In other embodiments of the invention, a raw latex obtained from aCroton species or a Calophyllum species or an extract obtained from aCroton species or a Calophyllum species that are not specificallypolymeric proanthocyanidin compositions are useful in the methods of thepresent invention. Exemplary extracts are described in Persinos et al.,1979, J. Pharma. Sci. 68:124 and Sethi, 1977, Canadian J. Pharm. Sci.12:7.

In particular embodiments, inhibitor molecules of the invention usefulin the methods of the present invention are antisense oligonucleotidesto the CFTR nucleotide sequence that inhibit expression of CFTR. Suchantisense nucleic acids useful in the methods of the present inventionare oligonucleotides that are double-stranded or single-stranded, RNA orDNA or a modification or derivative thereof, which can be directlyadministered, or which can be produced intracellularly by transcriptionof exogenous, introduced sequences. The antisense nucleic acids can betested by known methods to confirm their ability to inhibit CFTRfunction by inhibiting expression of CFTR.

In certain embodiments, the CFTR antisense nucleic acids can be of atleast six nucleotides and can be preferably oligonucleotides (rangingfrom 6 to about 50 oligonucleotides). In specific aspects, theoligonucleotide is at least 10 nucleotides, at least 15 nucleotides, atleast 100 nucleotides, or at least 200 nucleotides in length. Theoligonucleotides can be DNA or RNA or chimeric mixtures or derivativesor modified versions thereof, single-stranded or double-stranded. Theoligonucleotide can be modified at the base moiety, sugar moiety, orphosphate backbone using techniques well known in the art. Theoligonucleotide may include other appending groups such as peptides, orother compounds that inhibit systemic absorption, particularly whenadministered orally. The oligonucleotide may be modified at any positionon its structure with substituents generally known in the art.

An RNA interference (RNAi) molecule can be used to as an inhibitor ofCFTR function by decreasing expression of CFTR. RNAi is defined as theability of double-stranded RNA (dsRNA) to suppress the expression of agene corresponding to its own sequence. RNAi is also calledpost-transcriptional gene silencing or PTGS. Since the only RNAmolecules normally found in the cytoplasm of a cell are molecules ofsingle-stranded mRNA, the cell has enzymes that recognize and cut dsRNAinto fragments containing 21-25 base pairs (approximately two turns of adouble helix). The antisense strand of the fragment separates enoughfrom the sense strand so that it hybridizes with the complementary sensesequence on a molecule of endogenous cellular mRNA (e.g., a human CFTR).This hybridization triggers cutting of the mRNA in the double-strandedregion, thus destroying its ability to be translated into a polypeptide.Introducing dsRNA corresponding to a particular gene thus knocks out thecell's own expression of that gene in particular tissues and/or at achosen time.

In other embodiments, inhibitors of CFTR function or expression can beaptamers of CFTR. As is known in the art, aptamers are macromoleculescomposed of nucleic acid (e.g., RNA, DNA) that bind tightly to aspecific molecular target (e.g., CFTR). A particular aptamer may bedescribed by a linear nucleotide sequence and is typically about 15-60nucleotides in length. In addition to high specificity, aptamers havevery high affinities for their targets (e.g., affinities in thepicomolar to low nanomolar range for proteins). Selection of aptamersthat can bind to CFTR or a fragment thereof can be achieved throughmethods known in the art. For example, aptamers can be selected usingthe SELEX (Systematic Evolution of Ligands by Exponential Enrichment)method (Tuerk and Gold, 1990, Science 249:505-510.

In certain embodiments, an antibody that binds to the CFTR can be usedin the methods of the present invention. Exemplary antibodies to CFTRare described in WO 95/06066, the disclosure of which is incorporatedherein by reference in its entirety. In a preferred embodiment, theantibody to CFTR binds to the extracellular portion of the CFTR. Methodsfor making antibodies to CFTR or an immunogenic fragment, preferably anextracellular fragment of CFTR are well known in the art. Once theantibody has been produced, it can be screened using known methods,supra, for determining its effectiveness in inhibiting CFTR function,such as chloride-ion transport.

According to the invention, CFTR, its fragments or other derivatives, oranalogs thereof, may be used as an immunogen to generate antibodieswhich recognize such an immunogen for use in the methods of theinvention. Such antibodies include but are not limited to polyclonal,monoclonal, chimeric, single chain, Fab fragments, and an Fab expressionlibrary. In one embodiment, antibodies to a portion of CFTR exposed onthe outside of the cell are produced.

Antibody fragments which contain the idiotype of CFTR can be generatedby known techniques. For example, such fragments include but are notlimited to: the F(ab′)2 fragment which can be produced by pepsindigestion of the antibody molecule; the Fab′ fragments which can begenerated by reducing the disulfide bridges of the F(ab′)2 fragment, andthe Fab fragments which can be generated by treating the antibodymolecule with papain and a reducing agent. In the production ofantibodies, screening for the desired antibody can be accomplished bytechniques known in the art, e.g. ELISA (enzyme-linked immunosorbentassay).

Any method known in the art that measures chloride-ion transport can beused or modified appropriately to test whether a candidate molecule caninhibit chloride-ion transport. For example, chloride-ion transport canbe used to test a candidate molecule for its effect on CFTR function. Anexemplary method for testing whether a candidate compound inhibits CFTRfunction is described in U.S. Pat. No. 5,234,922. Briefly, a candidatemolecule is contacted with a cell expressing CFTR (endogenously orrecombinantly), optionally with an activator of CFTR such as a cAMPagonist (e.g., CPT-cAMP, db-cAMP, forskolin, IBMX, cholera toxin, E.coli lipopolysaccharide) and whole-cell membrane currents are measured.If the current is less in the presence of the candidate molecule ascompared to a cell not contacted with the candidate molecule, themolecule inhibits CFTR function. Another exemplary screening methodwhich uses Ussing chambers to measure the chloride-mediated current isdescribed in Schuier et al., 2005, J. Nutr. 135:2320-2325. A similarmethod is described in Fischer et al., 2004, J. Ethnopharm. 93:351-357.A particular high-throughput method for screening for inhibitors of CFTRfunction is described in Galietta et al., 2004, Curr. Opin. Pharmacol.4:497-503.

In one embodiment, the method comprises contacting a candidate compoundand an activator of CFTR function with a cell expressing CFTR, measuringthe chloride-ion-dependent current produced by the cell, and comparingthe current produced by the contacted cell to the current produced by asecond cell contacted only with the activator of CFTR function, whereina lower level of current produced by the cell contacted with thecandidate molecule as compared to the level of current produced by thesecond cell indicates that the candidate molecule is an inhibitor ofCFTR function. In one aspect of this embodiment, the activator of CFTRfunction is a cAMP agonist. In another aspect, CFTR is recombinantlyexpressed in the cells.

In another embodiment of the present invention, combinatorial chemistrycan be used to identify agents that inhibit chloride-ion transport, suchas those that inhibit CFTR function. Combinatorial chemistry is capableof creating libraries containing hundreds of thousands of compounds,many of which may be structurally similar. While high throughputscreening programs are capable of screening these vast libraries foraffinity for known targets, new approaches have been developed thatachieve libraries of smaller dimension but which provide maximumchemical diversity. (See e.g., Matter, 1997, Journal of MedicinalChemistry 40:1219-1229).

In a preferred embodiment, the inhibitor molecules used in the methodsof the invention are not substantially systemically absorbed whenadministered orally. Small molecules and other drugs that aresystemically absorbed when delivered orally can be modified to preventsystemic absorption. Such modifications are known in the art. Forexample, an inhibitor molecule of the invention such as a small moleculeinhibitor may be covalently attached to a non-systemically absorbedcompound that is substantially inert in the gastrointestinal tract anddoes not interfere with the function of the inhibitor molecule. Suchnon-systemically absorbed compounds include various polymers. Thepolymers that are preferably used with the inhibitor molecules of theinvention resist degradation and absorption in the gastrointestinalsystem, i.e., the polymers do not substantially break down underphysiological conditions in the stomach and intestines into fragmentswhich are absorbable by body tissues. Polymers that have anon-hydrolyzable backbone which is substantially inert under conditionsencountered in the gastrointestinal tract, are preferred. Such polymerswill preferably have a sufficiently high molecular weight to resistabsorption, partially or completely, from the gastrointestinal tractinto other parts of the body. The polymers can have molecular weightsranging from about 500 Daltons to about 500,000 Daltons, preferably fromabout 2,000 Daltons to about 150,000 Daltons. Examples of suitablepolymers include but are not limited to, polysaccharides, polyethyleneglycol polymers, cellulosic polymers, polystyrene polymers, polyacrylatepolymers, and polyamide polymers.

Polymer molecules that are not systemically absorbable and which aresubstituted by one or more of tolbutamide, glibenclamide, diazoxide,lemakalim, minoxidil sulfate, epicatechin, catechin, quercetin, morin,luteolin, baicalein, apigenin, fluorescein,3-[(3-trifluoromethy)phenyl]-5-[(3-carboxyphenyl)methylene]-2-thioxo-4-thiazolidinone, verapamil, nifedipine, diltiazem,loperamide, diphenylamine-2-carboxylate (DPC),5-nitro-2(3-phenylpropylamino)benzoate (NPPB), anthracene-9-carboxylicacid (9-AC), flufenamic acid (FFA), 9-(tetrahydro-2-furyl) adenine(SQ22536), 2′,5′-dideoxyadenosine, sparteine, and their derivatives,fragments and/or analogs of can be screened for inhibitory activity ofCFTR function.

The present invention encompasses methods for treating and/or preventingone or more symptoms associated with diarrhea-predominant irritablebowel syndrome (d-IBS), in warm blooded animals, including male andfemale humans, which symptoms include, but are not limited to, pain,abdominal discomfort, diarrhea, presence of urgency, abnormal stoolfrequency and abnormal stool consistency. The methods of the inventiongenerally comprise administering to a subject in need of d-IBS treatmentan inhibitor of chloride-ion transport in accordance with the invention.In a preferred embodiment, the inhibitor is orally administered and isnot systemically absorbed. Preferably, the patient is a human female.

In one embodiment, the present invention provides a method of treatingpain and diarrhea associated with d-IBS comprising administering to apatient in need of such treatment, an amount of a molecule that inhibitssecretion of chloride ions from a cell (inhibitor molecule) effective totreat pain and diarrhea associated with d-IBS. In another embodiment,the present invention provides a method of treating abdominal discomfortand diarrhea associated with d-IBS comprising administering to a patientin need of such treatment, an amount of a molecule that inhibitssecretion of chloride ions from a cell (inhibitor molecule) effective totreat abdominal discomfort and diarrhea associated with d-IBS. Incertain embodiments, the inhibitor molecule is co-administered with ananalgesic and/or anti-inflammatory compound, such as one that inhibitsCOX-2 and preferably inhibits COX-2 over COX-1.

In one embodiment, the present invention provides a method of treatingpain associated with d-IBS comprising administering to a patient in needof such treatment, an amount of a molecule that inhibits secretion ofchloride ions from a cell (inhibitor molecule) effective to treat painassociated with d-IBS. In another embodiment, the present inventionprovides a method of treating abdominal discomfort associated with d-IBScomprising administering to a patient in need of such treatment, anamount of a molecule that inhibits secretion of chloride ions from acell (inhibitor molecule) effective to treat abdominal discomfortassociated with d-IBS. In certain embodiments, the inhibitor molecule isco-administered with an analgesic and/or anti-inflammatory compound,such as one that inhibits COX-2 and preferably inhibits COX-2 overCOX-1.

The inhibitor molecules of the invention can be administered in a singleor a divided dosage from one, two, three or four times per day. In aparticular embodiment, the inhibitor molecule is administered twicedaily. In yet another embodiment, the inhibitor molecule is administeredtwice daily for at least two consecutive days. In yet anotherembodiment, the inhibitor molecule is administered for at least a periodof time selected from the group consisting of 24 hours, 48 hours, 72hours, 96 hours, one week, two weeks, one month, two months, and threemonths. In certain embodiments, where d-IBS is a chronic condition, theinhibitor molecule is taken indefinitely.

Pain and discomfort can be measured by any method known in the art, forinstance on a pain or discomfort scale in which a patient assigns thelevel of pain or discomfort on a scale of 0 to 5, with 0 being no painor discomfort and 5 being assigned the highest level of pain ordiscomfort. In certain embodiments, the alleviation of pain ordiscomfort is measured by a lowering of the average level of pain ordiscomfort, an increase in the number of pain- or discomfort-free days.In certain embodiments, the number of pain- or discomfort-free days isincreased by at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, or byat least 50% compared to before treatment. In other embodiments, thelevel of pain or discomfort decreased by at least 0.1, 0.2, 0.3, 0.4 orby at least 0.5 units compared to before treatment.

In another embodiment, the present invention provides a method oftreating diarrhea associated with d-IBS comprising administering to apatient in need of such treatment, an amount of a molecule that inhibitssecretion of chloride ions from a cell (inhibitor molecule) effective totreat the diarrhea associated with d-IBS, with the proviso that theinhibitor molecule is not a polymeric proanthocyanidin compositionisolated from Croton spp. or Calophyllum spp. or that the inhibitormolecule is not crofelemer. In yet another embodiment, the presentinvention provides a method of treating abnormal stool frequency,abnormal stool consistency or presence of urgency associated with d-IBScomprising administering to a patient in need of such treatment, anamount of a molecule that inhibits secretion of chloride ions from acell (inhibitor molecule) effective to treat the abnormal stoolfrequency, abnormal stool consistency or presence of urgency associatedwith d-IBS, with the proviso that the inhibitor molecule is not apolymeric proanthocyanidin composition isolated from Croton spp. orCalophyllum spp. or that the inhibitor molecule is not crofelemer.

In particular embodiments, stool frequency is decreased by at least 10%,20%, 30%, 40% or 50% compared to before treatment. In other embodiments,stool frequency is decreased by at least one bowel movement per daycompared to before treatment. In other embodiments, stool consistency isincreased, i.e., there is a decrease in the amount of water in thestool, by at least 10%, 20%, 25%, 30%, 40%, or 50% compared to beforetreatment. In yet other embodiments, presence of urgency is decreased byat least 10%, 20%, 30%, 40%, or by at least 50% compared to beforetreatment.

In another embodiment, the present invention provides a method oftreating diarrhea associated with d-IBS comprising orally administeringto a patient in need of such treatment, an amount ofenterically-protected crofelemer (CAS 148465-45-6) effective to treatthe diarrhea associated with d-IBS, in which said amount is betweenabout 50 mg per day and about 750 mg per day. In yet another embodiment,the present invention provides a method of treating abnormal stoolfrequency, abnormal stool consistency or presence of urgency associatedwith d-IBS comprising orally administering to a patient in need of suchtreatment, an amount of enterically-protected crofelemer effective totreat the abnormal stool frequency, abnormal stool consistency orpresence of urgency associated with d-IBS, in which said amount isbetween about 50 mg per day and about 750 mg per day.

In another embodiment, the present invention provides a method oftreating diarrhea associated with d-IBS comprising orally administeringto a patient in need of such treatment, an amount of crofelemer (CAS148465-45-6) effective to treat the diarrhea associated with d-IBS. Inyet another embodiment, the present invention provides a method oftreating abnormal stool frequency, abnormal stool consistency orpresence of urgency associated with d-IBS comprising orallyadministering to a patient in need of such treatment, an amount ofcrofelemer effective to treat the abnormal stool frequency, abnormalstool consistency or presence of urgency associated with d-IBS. In suchembodiments where crofelemer is otherwise formulated (not entericallyprotected) the dosage of crofelemer administered is bioequivalent to adosage of about 50 mg per day to about 750 mg per day of orallyadministered enterically-protected crofelemer. One such exemplaryformulation is a controlled-release formulation.

In another embodiment, the present invention provides a method oftreating diarrhea associated with d-IBS comprising administering to apatient in need of such treatment, an amount of a polymericproanthocyanidin composition isolated from Croton spp. or Calophyllumspp. effective to treat the diarrhea associated with d-IBS, in whichsaid amount is bioequivalent to an orally administered dose of about 50mg per day to about 750 mg per day of crofelemer. In yet anotherembodiment, the present invention provides a method of treating abnormalstool frequency, abnormal stool consistency or presence of urgencyassociated with d-IBS comprising administering to a patient in need ofsuch treatment, an amount of a polymeric proanthocyanidin compositionisolated from Croton spp. or Calophyllum spp. effective to treat theabnormal stool frequency, abnormal stool consistency or presence ofurgency associated with d-IBS, in which said amount is bioequivalent toan orally administered dose of about 50 mg per day to about 750 mg perday of crofelemer.

Methods of administering an inhibitor of chloride-ion transport include,but are not limited to, parenteral administration (e.g., intradermal,intramuscular, intraperitoneal, intravenous and subcutaneous) andmucosal (e.g., intranasal and oral routes). In a specific embodiment, aninhibitor molecule is administered intramuscularly, intravenously, orsubcutaneously. Compositions comprising an inhibitor molecule may beadministered by any convenient route, for example, by infusion or bolusinjection, by absorption through epithelial or mucocutaneous linings(e.g., oral mucosa, rectal and intestinal mucosa, etc.) and may beadministered together with other biologically active agents.Administration can be systemic or local. Preferably, the inhibitormolecule is orally administered.

In certain preferred embodiments of the present invention, the inhibitormolecule is crofelemer (CAS 148465-45-6). In other preferredembodiments, the inhibitor molecule is administered orally. In yet otherpreferred embodiments, the inhibitor molecule is formulated so as toprotect the composition from the stomach environment, i.e., from theacidic environment and digestive proteins found in the stomach. In apreferred embodiment, administration is by oral route and the inhibitormolecule is enteric protected crofelemer.

In certain preferred embodiments, crofelemer is orally administered inan enteric protected form (enteric coated) in a total amount of not morethan about 750 mg/day. As used herein, about means within the margin oferror. In specific embodiments, the enteric coated crofelemer is orallyadministered to a subject in an amount of from about 50 mg/day to 750mg/day. In another embodiment, the enteric coated crofelemer is orallyadministered to a subject in a total amount of not more than about 500mg/day. In specific embodiments, the enteric coated crofelemer is orallyadministered to a subject in an amount of from about 50 mg/day to 500mg/day. In other embodiments, the enteric coated crofelemer is orallyadministered to a subject at not more than about 700 mg/day, about 650mg/day, about 600 mg/day, about 550 mg/day, about 500 mg/day, about 450mg/day, about 400 mg/day, about 350 mg/day, about 300 mg/day, about 250mg/day, about 200 mg/day, about 150 mg/day or about 100 mg/day ofenteric coated crofelemer. In yet another embodiment, the enteric coatedcrofelemer is orally administered to a subject in an amount from about100 mg/day to 750 mg/day. In other embodiments, the enteric coatedcrofelemer is orally administered to a subject in an amount of fromabout 125 mg/day to about 500 mg/day, from about 250 mg/day to about 500mg/day, from about 250 mg/day to about 450 mg/day, from about 250 mg/dayto about 400 mg/day, from about 250 mg/day to about 350 mg/day, or fromabout 250 mg/day to about 300 mg/day. In other particular embodiments,the total dosage of the enteric coated crofelemer orally administered toa subject is about 50 mg, about 55 mg, about 60 mg, about 65 mg, about70 mg, about 75 mg, about 80 mg, about 85 mg, about 90 mg, about 95 mg,about 100 mg, about 105 mg, about 110 mg, about 115 mg, about 120 mg,about 125 mg, about 130 mg, about 135 mg, about 140 mg, about 145 mg,about 150 mg, about 155 mg, about 160 mg, about 165 mg, about 170 mg,about 175 mg, about 180 mg, about 185 mg, about 190 mg, about 195 mg,about 200 mg, about 205 mg, about 210 mg, about 215 mg, about 220 mg,about 225 mg, about 230 mg, about 235 mg, about 240 mg, about 245 mg,about 250 mg, about 255 mg, about 260 mg, about 265 mg, about 270 mg,about 275 mg, about 280 mg, about 285 mg, about 290 mg, about 295 mg,about 300 mg, about 305 mg, about 310 mg, about 315 mg, about 320 mg,about 325 mg, about 330 mg, about 335 mg, about 340 mg, about 345 mg,about 350 mg, about 355 mg, about 360 mg, about 365 mg, about 370 mg,about 375 mg, about 380 mg, about 385 mg, about 390 mg, about 395 mg,about 400 mg, about 405 mg, about 410 mg, about 415 mg, about 420 mg,about 425 mg, about 430 mg, about 435 mg, about 440 mg, about 445 mg,about 450 mg, about 455 mg, about 460 mg, about 465 mg, about 470 mg,about 475 mg, about 480 mg, about 485 mg, about 490 mg, about 495 mg, orabout 500 mg once, twice, or three-times per day.

In other embodiments of the invention, the inhibitor molecule, whether aproanthocyanidin polymer composition or an inhibitor of CFTR function,is preferably given at a dosage that is bioequivalent to orallyadministered enteric coated crofelemer at a dosage of about 50 mg perday to about 750 mg/day or any of the doses listed above. In oneembodiment, bioequivalency is a sufficient dose of an inhibitor moleculeto produce similar therapeutic effects as seen with another inhibitormolecule at a particular dosage, e.g., crofelemer at a dosage of about50 mg per day to about 750 mg per day. In another embodiment,bioequivalency is as defined by, or is as determined in accordance withmethods approved by, the U.S. Food and Drug Administration.

In a preferred embodiment, crofelemer is enteric coated so as to protectit from degradation by the acidic conditions of the stomach and/or frominteractions with proteins, such as pepsin, present in the stomach,i.e., an enteric protected formulation. In a specific embodiment,crofelemer is in tablet form. In yet another specific embodiment, thetablet is enteric coated, e.g., EUDRAGIT®. In a preferred embodiment,crofelemer is formulated as an enteric coated bead or granule in anenteric coated capsule shell. In another embodiment, crofelemer isformulated in a delayed release composition, e.g., Merck GEM, Alza OROS,wax matrix (release is delayed primarily until the formulation passesout of the stomach and into the intestine).

In certain embodiments, the inhibitor molecule is formulated with acompound or compounds which neutralize stomach acid. Alternatively, thepharmaceutical composition containing the inhibitor molecule isadministered either concurrent with or subsequent to or afteradministration of a pharmaceutical composition which neutralize stomachacid. Compounds, such as antacids, which are useful for neutralizingstomach acid include, but are not limited to, aluminum carbonate,aluminum hydroxide, bismuth subnitrate, bismuth subsalicylate, calciumcarbonate, dihydroxyaluminum sodium carbonate, magaldrate, magnesiumcarbonate, magnesium hydroxide, magnesium oxide, and mixtures thereof.Compounds that are able to reduce the secretion of stomach acid and/orare able to reduce the acidity of stomach fluid are well known in theart and include, but are not limited to, antacids (aluminum hydroxide,aluminum carbonate, aluminum glycinate, magnesium oxide, magnesiumhydroxide, magnesium carbonate, calcium carbonate, sodium bicarbonate),stomach acid blockers (cimetidine (Tagamet™), famotidine (Mylanta™,Pepcid™), nizatidine (Axid™), ranitidine (Zantac™), omeprazole(Zegerid™) and a combination of any of the foregoing. In general, anydrug that has been approved for sale by the relevant government agencyand is able to reduce the production of stomach acid and/or reduce theacidity of stomach fluid can be administered in combination with aninhibitor molecule, such as crofelemer, in accordance with the methodsof the invention.

In other embodiments, the inhibitor molecule is administered with othercompounds which are useful in treating diarrhea or pain. Such compoundsinclude, but are not limited to, COX-2 inhibitors such as 5-ASA,sulfasalazine, mesalamine, APAZA, as well as other commerciallyavailable COX-2 inhibitors such as celecoxib and rofecoxib. Preferably,such compounds are not systemically absorbed or are modified so as tonot be systemically absorbed.

In a particular embodiment where crofelemer is not enteric coated,crofelemer is formulated with one or more compounds that are able toreduce the secretion of stomach acid and/or able to reduce the acidityof stomach fluid. Preferably, the dosage of crofelemer to be given inthis formulation is a dosage that is bioequivalent to orallyadministered enteric coated crofelemer at a dosage of about 50 mg perday to about 750 mg per day. In an exemplary embodiment, crofelemer isformulated in a controlled release (delayed release) composition.

In other embodiments, the inhibitor molecules of the invention can beadministered in combination with analgesic or anti-inflammatory agents.In a preferred embodiment, the analgesic or anti-inflammatory agent isformulated or modified such that it is not substantially systemicallyabsorbed, i.e., only 20%, 15%, 10%, 5%, 4%, 3%, 2%, 1% or 0.5% absorbedof the dosage given.

The present invention also provides pharmaceutical formulations ofchloride-ion transport inhibitors (inhibitor molecules) of the inventioncomprising an inhibitor molecule along with a pharmaceuticallyacceptable vehicle, at a dose which is therapeutically effective attreating and/or ameliorating one or more symptoms associated with d-IBS.In one embodiment, a directly compressible proanthocyanidin polymercomposition (i.e., that can be directly compressed, without excipients,into a tablet of pharmaceutically acceptable hardness and friability)compressed into a tablet, optionally with a lubricant, such as but notlimited to magnesium stearate, is enteric coated. In another embodiment,the pharmaceutical compositions containing the inhibitor molecule of theinvention alternatively include one or more substances that eitherneutralize stomach acid and/or enzymes or are active to preventsecretion of stomach acid. These formulations can be prepared by methodsknown in the art, see, e.g., methods described in Remington'sPharmaceutical Sciences, 18th Ed., ed. Alfonso R. Gennaro, MackPublishing Co., Easton, Pa., 1990.

In another preferred embodiment, the pharmaceutical compositioncomprises a proanthocyanidin polymer composition prepared from a Crotonspp, the dosage of which does not exceed 750 mg per day, preferably lessthan 250 mg/day. In a preferred embodiment, the proanthocyanidin polymercomposition of the present invention is crofelemer (CAS 148465-45-6).

The inhibitor molecule can be provided in any therapeutically acceptablepharmaceutical form. The pharmaceutical composition can be formulatedfor oral administration as, for example but not limited to, drugpowders, crystals, granules, small particles (which include particlessized on the order of micrometers, such as microspheres andmicrocapsules), particles (which include particles sized on the order ofmillimeters), beads, microbeads, pellets, pills, microtablets,compressed tablets or tablet triturates, molded tablets or tablettriturates, and in capsules, which are either hard or soft and containthe composition as a powder, particle, bead, solution or suspension. Thepharmaceutical composition can also be formulated for oraladministration as a solution or suspension in an aqueous liquid, as aliquid incorporated into a gel capsule or as any other convenientformulation for administration, or for rectal administration, as asuppository, enema or other convenient form. The inhibitor molecule ofthe invention can also be provided as a controlled release system (see,e.g., Langer, 1990, Science 249: 1527-1533).

The pharmaceutical formulation can also include any type ofpharmaceutically acceptable excipients, additives or vehicles. Forexample, but not by way of limitation, diluents or fillers, such asdextrates, dicalcium phosphate, calcium sulfate, lactose, cellulose,kaolin, mannitol, sodium chloride, dry starch, sorbitol, sucrose,inositol, powdered sugar, bentonite, microcrystalline cellulose, orhydroxypropylmethylcellulose may be added to the inhibitor molecule toincrease the bulk of the composition. Also, binders, such as but notlimited to, starch, gelatin, sucrose, glucose, dextrose, molasses,lactose, acacia gum, sodium alginate, extract of Irish moss, panwar gum,ghatti gum, mucilage of isapgol husks, carboxymethylcellulose,methylcellulose, polyvinylpyrrolidone, Veegum and starch arabogalactan,polyethylene glycol, ethylcellulose, and waxes, may be added to theformulation to increase its cohesive qualities. Additionally,lubricants, such as but not limited to, talc, magnesium stearate,calcium stearate, stearic acid, hydrogenated vegetable oils,polyethylene glycol, sodium benzoate, sodium acetate, sodium chloride,leucine, carbowax, sodium lauryl sulfate, and magnesium lauryl sulfatemay be added to the formulation. Also, glidants, such as but not limitedto, colloidal silicon dioxide or talc may be added to improve the flowcharacteristics of a powdered formulation. Finally, disintegrants, suchas but not limited to, starches, clays, celluloses, algins, gums,crosslinked polymers (e.g., croscarmelose, crospovidone, and sodiumstarch glycolate), Veegum, methylcellulose, agar, bentonite, celluloseand wood products, natural sponge, cation-exchange resins, alginic acid,guar gum, citrus pulp, carboxymethylcellulose, or sodium lauryl sulfatewith starch may also be added to facilitate disintegration of theformulation in the intestine.

In one aspect of this embodiment, crofelemer is formulated for oraladministration. In other aspects, the pharmaceutical dosage form isformulated to protect the inhibitor molecule, e.g., crofelemer, fromdegradation by the acidic conditions of the stomach and frominteractions with proteins, such as pepsin, present in the stomach.Thus, in a preferred aspect, the formulation is enteric coated. Forexample, the enteric coated formulation is enteric coated tablets, beadsor granules, which optionally contain a lubricant such as, but notlimited to, magnesium stearate. The enteric coated formulations includeenteric coated beads in a capsule, enteric coated microspheres in acapsule, enteric coated microspheres provided in a suspension or mixedwith food, which suspensions are particularly convenient for pediatricadministration, and enteric coated compressed tablets. The capsule canbe a hard-shell gelatin capsule or a cellulose capsule. In particular,the pharmaceutical composition is formulated as an enteric coatedcapsule. In one specific aspect, a proanthocyanidin polymer compositionis administered in tablet form, which tablet is backfilled withmicrocrystalline cellulose.

In one embodiment, the inhibitor molecule is directly compressed, thatis, the inhibitor molecule, with or without any excipients, can becompressed into a tablet, or other pharmaceutical formulation, that hasa pharmaceutically acceptable hardness and friability. Preferably, thedirectly compressible pharmaceutical composition can be compressed intotablets having a hardness of greater than 4 kp (kiloponds), preferably ahardness of 8 to 14 kp, more preferably a hardness of 10 to 13 kp. Adirectly compressible composition can be compressed into a tablet thathas a friability of not more than 1% loss in weight, preferably lessthan 0.8% loss in weight, more preferably less than 0.5% loss in weight.

In a preferred embodiment, the directly compressible formulationconsists of 99.93% crofelemer and 0.07% magnesium stearate and is coatedwith a methacrylic acid copolymer. In another preferred embodiment, thepharmaceutical formulation contains a directly compressible inhibitormolecule but no excipients, additives or vehicles other than an entericcoating; however, the formulation may contain a lubricant, such as butnot limited to, magnesium stearate. Preferably, a directly compressedproanthocyanidin polymer composition formulation is formulated as atablet of pharmaceutically acceptable hardness (greater than 4 kp,preferably 8-14 kp, and more preferably 10-13 kp) and friability (notmore than 1% loss in weight, preferably less than 0.8% loss in weight,and more preferably less than 0.5% loss in weight).

In a more preferred embodiment, the inhibitor molecule is entericcoated. Enteric coatings are those coatings that remain intact in thestomach, but will dissolve and release the contents of the dosage formonce it reaches the small intestine. A large number of enteric coatingsare prepared with ingredients that have acidic groups such that, at thevery low pH present in the stomach, i.e. pH 1.5 to 2.5, the acidicgroups are not ionized and the coating remains in an undissociated,insoluble form. At higher pH levels, such as in the environment of theintestine, the enteric coating is converted to an ionized form, whichcan be dissolved to release the inhibitor molecule. Other entericcoatings remain intact until they are degraded by enzymes in the smallintestine, and others break apart after a defined exposure to moisture,such that the coatings remain intact until after passage into the smallintestines.

Polymers which are useful for the preparation of enteric coatingsinclude, but are not limited to, shellac, starch and amylose acetatephthalates, styrene-maleic acid copolymers, cellulose acetate succinate,cellulose acetate phthalate (CAP), polyvinylacetate phthalate (PVAP),hydroxypropylmethylcellulose phthalate (grades HP-50 and HP-55),ethylcellulose, fats, butyl stearate, and methacrylic acid-methacrylicacid ester copolymers with acid ionizable groups (including “ACRYLEZE®”and “EUDRAGIT®”), such as “EUDRAGIT® L 30D”, “EUDRAGIT® RL 30D”,“EUDRAGIT® RS 30D”, “EUDRAGIT® L 100-55”, and “EUDRAGIT® L 30D-55”. In apreferred embodiment, the pharmaceutical composition contains aninhibitor of chloride-ion transport, such as a proanthocyanidinpolymeric composition, and the enteric coating polymer “EUDRAGIT® L30D”, an anionic copolymer of methacrylic acid and methyl acrylate witha mean molecular weight of 250,000 Daltons. In another preferredembodiment, the enteric coating polymer is “EUDRAGIT® L 30D-55”.

The disintegration of the enteric coating occurs either by hydrolysis byintestinal enzymes or by emulsification and dispersion by bile salts,depending upon the type of coating used. For example, esteraseshydrolyze esterbutyl stearate to butanol and stearic acid and, as thebutanol dissolves, the stearic acid flakes off of the medicament.Additionally, bile salts emulsify and disperse ethylcellulose,hydroxypropylmethylcellulose, fats and fatty derivatives. Other types ofcoatings are removed depending on the time of contact with moisture, forexample coatings prepared from powdered carnauba wax, stearic acid, andvegetable fibers of agar and elm bark rupture after the vegetable fibersabsorb moisture and swell. The time required for disintegration dependsupon the thickness of the coating and the ratio of vegetable fibers towax.

Application of the enteric coating to the inhibitor molecule of theinvention can be accomplished by any method known in the art forapplying enteric coatings. For example, but not by way of limitation,the enteric polymers can be applied using organic solvent basedsolutions containing from 5 to 10% w/w polymer for spray applicationsand up to 30% w/w polymer for pan coatings. Solvents that are commonlyin use include, but are not limited to, acetone, acetone/ethyl acetatemixtures, methylene chloride/methanol mixtures, and tertiary mixturescontaining these solvents. Some enteric polymers, such as methacrylicacid-methacrylic acid ester copolymers can be applied using water as adispersant. The volatility of the solvent system must be tailored toprevent sticking due to tackiness and to prevent high porosity of thecoating due to premature spray drying or precipitation of the polymer asthe solvent evaporates.

Furthermore, plasticizers can be added to the enteric coating to preventcracking of the coating film. Suitable plasticizers include the lowmolecular weight phthalate esters, such as diethyl phthalate, acetylatedmonoglycerides, triethyl citrate, polyethyl glycoltributyl citrate andtriacetin. Generally, plasticizers are added at a concentration of 10%by weight of enteric coating polymer weight. Other additives such asemulsifiers, for example detergents and simethicone, and powders, forexample talc, may be added to the coating to improve the strength andsmoothness of the coating. Additionally, pigments may be added to thecoating to add color to the pharmaceutical formulation.

In preferred embodiments, a pharmaceutical composition of the inhibitormolecule is provided as enteric coated beads in hard-shell gelatincapsules. In a preferred embodiment, proanthocyanidin polymer beads areprepared by mixing a proanthocyanidin polymer composition withhydroxypropylmethylcellulose and layering the mixture onto nonpareilseeds (sugar spheres). In a more preferred embodiment, crofelemer, whichis directly compressible, without any excipients, additives or vehiclesother than an enteric coating, is milled and fractionated into beads(i.e., as beads that do not contain the nonpareil sugar seeds). Thebeads may be covered with a seal coat of Opadry Clear (mixed withwater). A preferred enteric coating of the beads is “EUDRAGIT™ L 30D” or“EUDRAGIT™ L 30D-55” applied as an aqueous dispersion containing 20%-30%w/w dry polymer substance, which is supplied with 0.7% sodium laurylsulfate NF (SLS) and 2.3% polysorbate 80 NF (Tween™ 20) as emulsifiers,to which plasticizers, such as polyethylene glycol and/or citric acidesters, are added to improve the elasticity of the coating, and talc canbe added to reduce the tendency of the enteric coating polymer toagglutinate during the application process and to increase thesmoothness of the film coating.

In a preferred formulation, the final composition of enteric coatedproanthocyanidin polymer composition beads containing the nonpareilseeds is 17.3% w/w nonpareil seeds, 64.5% w/w proanthocyanidin polymercomposition, 1.5% w/w hydroxypropylmethylcellulose, 0.5% w/w Opadryclear, 14.5% w/w “EUDRAGIT™ L 30D”, 1.45% w/w triethyl citrate, and0.25% w/w glyceryl monostearate. This pharmaceutical formulation may beprepared by any method known in the art or by the method described inExample 1, infra.

A preferred formulation of the proanthocyanidin polymer compositionbeads not containing the nonpareil seeds is 78% w/w directlycompressible proanthocyanidin polymer composition (e.g., isolated by themethod described in the Examples), 0.76% w/w Opadry Clear, 19% w/w“EUDRAGIT™ L 30D-55”, 1.9% triethyl citrate, and 0.34% w/w glycerylmonostearate. This pharmaceutical formulation may be prepared by anymethod known in the art or by the method described in Example 2, infra.

Another preferred formulation contains 54.58% w/w proanthocyanidinpolymer composition beads (without non-pareil seeds and made of adirectly compressible proanthocyanidin polymer composition), 1.78% w/wOpadry Clear, 39% w/w “EUDRAGIT™ L 30D-55”, 3.9% triethylcitrate, and0.74% w/w glyceryl monostearate.

In another embodiment, the pharmaceutical composition comprising theinhibitor molecule of the invention is formulated as enteric coatedgranules or powder (microspheres with a diameter of 300-500μ) providedin either hard shell gelatin capsules or suspended in an oral solutionfor pediatric administration. The enteric coated powder or granules mayalso be mixed with food, particularly for pediatric administration. Thispreparation may be prepared using techniques well known in the art, suchas the method described in Example 1C, infra.

In general, the granules and powder can be prepared using any methodknown in the art, such as but not limited to, crystallization,spray-drying or any method of comminution, preferably using a high speedmixer/granulator. Examples of high speed mixer/granulators include the“LITTLEFORD LODIGE™” mixer, the “LITTLEFORD LODIGE™” MGTmixer/granulator, and the “GRAL™” mixer/granulator. During thehigh-shear powder mixing, solutions of granulating agents, calledbinders, are sprayed onto the powder to cause the powder particles toagglomerate, thus forming larger particles or granules. Granulatingagents which are useful for preparing the granules, include but are notlimited to, cellulose derivatives (including carboxymethylcellulose,methylcellulose, and ethylcellulose), gelatin, glucose,polyvinylpyrrolidone (PVP), starch paste, sorbitol, sucrose, dextrose,molasses, lactose, acacia gum, sodium alginate, extract of Irish moss,panwar gum, ghatti gum, mucilage of isapol husks, Veegum and larcharabogalactan, polyethylene glycol, and waxes. Granulating agents may beadded in concentrations ranging from 1 to 30% of the mass of theparticles or granules.

The powder or granules are preferably coated using the fluidized bedequipment. The granules or powder may then be covered with a seal coatof Opadry Clear (mixed with water). A preferred enteric coating is“EUDRAGIT™ L 30D” applied as an aqueous dispersion containing 30% w/wdry polymer substance, which is supplied with 0.7% sodium lauryl sulfateNF (SLS) and 2.3% polysorbate 80 NF (Tween™ 20) as emulsifiers, to whichthe plasticizers, polyethylene glycol and citric acid esters, are addedto improve the elasticity of the coating, and talc is added to reducethe tendency of the enteric coating polymer to agglutinate during theapplication process and to increase the smoothness of the film coating.In a preferred embodiment, the final composition of an enteric coatedpowder is 81.8% w/w proanthocyanidin polymer composition, 1.5% w/whydroxypropylmethylcellulose, 0.5% w/w Opadry clear, 14.5% w/w“EUDRAGIT™ L 30D”, 1.45% w/w triethyl citrate, and 0.25% w/w glycerylmonostearate. The final composition of the enteric coated granules is81.8% w/w proanthocyanidin polymer composition, 10%polyvinylpyrrolidone, 1.5% w/w hydroxypropylmethylcellulose, 0.5% w/wOpadry clear, 14.5% w/w “EUDRAGIT™ L 30D”, 1.45% w/w triethyl citrate,and 0.25% w/w glyceryl monostearate.

The enteric coated granules or powder particles can further be suspendedin a solution for oral administration, particularly for pediatricadministration. The suspension can be prepared from aqueous solutions towhich thickeners and protective colloids are added to increase theviscosity of the solution to prevent rapid sedimentation of the coatedpowder particles or granules. Any material which increases the strengthof the hydration layer formed around suspended particles throughmolecular interactions and which is pharmaceutically compatible with theinhibitor molecule can be used as a thickener, such as but not limitedto, gelatin, natural gums (e.g., tragacanth, xanthan, guar, acacia,panwar, ghatti, etc.), and cellulose derivatives (e.g., sodiumcarboxymethylcellulose, hydroxypropylcellulose, andhydroxypropylmethylcellulose, etc.). Optionally, a surfactant such asTween™ may be added to improve the action of the thickening agent. Apreferred suspension solution is a 2% w/w hydroxypropylmethylcellulosesolution in water containing 0.2% Tween™.

The inhibitor molecule can also be formulated as enteric coated tablets.In one preferred embodiment, a proanthocyanidin polymer composition isgranulated with any pharmaceutically acceptable diluent (such as thoselisted above) by the methods described above for preparing the granules.Then, the granules are compressed into tablets using any method wellknown in the art, for example but not limited to, the wet granulationmethod, the dry granulation method or the direct compression method.Preferred diluents include, but are not limited to, microcrystallinecellulose (“AVICEL™ PH 200/300”) and dextrates (“EMDEX™”). Additionally,disintegrants, such as those described above, and lubricants, such thosedescribed above, may also be added to the tablet formulation. Apreferred tablet formulation contains 250 mg proanthocyanidin polymercomposition, 7 mg of the disintegrant “AC-DI-SOL™” (cross linked sodiumcarboxymethylcellulose), 1.75 mg of the lubricant magnesium stearate andthe weight of “AVICEL™ PH 200/300” necessary to bring the mixture up to350 mg. The tablets are coated with an enteric coating mixture preparedfrom 250 grams “EUDRAGIT™ L 30 D-55”, 7.5 grams triethyl citrate, 37.5grams talc and 205 grams water. This formulation may be prepared by anymethod well known in the art.

In a preferred embodiment, a directly compressible proanthocyanidinpolymer composition is made into granules by size reduction (e.g., asdescribed above) and mixed with a lubricant, preferably, magnesiumstearate. Then, the lubricated granules are compressed into tabletsusing any method well-known in the art, for example but not limited to,the direct compression method. Preferably, each tablet is 125 mgcontaining 99.6% w/w directly compressible proanthocyanidin polymercomposition and 0.40% w/w magnesium stearate. The tablets are thenpreferably coated with an enteric coating mixture of a 30% suspension(6.66 g in 22.22 g) of “EUDRAGIT™ L 30D-55”, 0.67 g triethyl citrate,1.67 g talc and 20.44 g purified water, per 100 grams of tablet. Thetablets can be prepared by any method known in the art or by the methoddescribed in Example 1E, infra.

In a more preferred embodiment, a directly compressible proanthocyanidinpolymer composition is formulated into core tablets of either 125 mg,250 mg or 500 mg containing 99.6% w/w directly compressibleproanthocyanidin polymer composition and 0.40% w/w magnesium stearate.The tablets are then preferably coated with an enteric coating mixture.The final composition of the tablets is 86.6% w/w directly compressibleproanthocyanidin polymer composition, 0.4% magnesium stearate, 6.5%“EUDRAGIT™ L30D-55”, 0.9% triethyl citrate, 2.87% talc, and 2.74% whitedispersion. The tablets can be prepared by any method known in the art,for example but not limited to the method described infra.

The compositions formed into small particles (which include particlessized on the order of micrometers, such as microspheres andmicrocapsules), particles (which include particles sized on the order ofmillimeters), drug crystals, pellets, pills and microbeads can be coatedusing a fluidized-bed process. This process uses fluidized-bedequipment, such as that supplied by “GLATT™”, “AEROMATIC™”, “WURSTER™”,or others, by which the composition cores are whirled up in a closedcylindrical vessel by a stream of air, introduced from below, and theenteric coat is formed by spray drying it onto the cores during thefluidization time. To coat tablets or capsules, Accela-Cota coatingequipment (“MANESTY™”) can be used. By this process, the tablets orcapsules are placed in a rotating cylindrical coating pan with aperforated jacket and spraying units are installed within the pan andthe dry air is drawn in through the rotating tablets or capsules. Anyother type of coating pan, such as the “COMPU-LAB™” pan, Hi-coates“GLATT™” immersion sword process, the “DRIAM™” Dricoater, “STEINBERG™”equipment, “PELLEGRINI™” equipment, or “WALTHER™” equipment can also beused.

The pharmaceutical formulations of the invention can also be used totreat d-IBS in non-human animals, particularly in farm animals, such asbut not limited to, bovine animals, swine, ovine animals, poultry (suchas chickens), and equine animals, and other domesticated animals such ascanine animals and feline animals. In particular, the pharmaceuticalformulations of the invention can be used to treat d-IBS disease innon-human animals, particularly food animals such as cattle, sheep andswine by incorporating the pharmaceutical compositions of the inventioninto the animal's feed.

According to the methods of the present invention, the pharmaceuticalcompositions of comprising chloride-ion transport inhibitors (inhibitormolecules) of the invention are administered to a subject in a totalamount that is bioequivalent to not more than 750 mg/day of orallyadministered enteric protected crofelemer. In specific embodiments,pharmaceutical compositions comprising crofelemer are administered to asubject in an amount of between about 50 mg per day and about 250mg/day.

In determining whether a subject has diarrhea-predominant IBS, anymethod can be used in the art to diagnose the subject including, but notlimited to, the Rome II criteria for diagnosis of irritable bowelsyndrome (Thompson et al., 1999, Gut 45 (Suppl II):II-43-II47). Briefly,the Rome II diagnostic criteria state that for at least 12 weeks, whichneed not be consecutive, in the preceding 12 months of abdominaldiscomfort or pain that has two of three features: (1) relief withdefecation, and/or (2) onset associated with a change in frequency ofstool; and/or (3) onset associated with a change in form (appearance) ofstool. The following symptoms cumulatively support the diagnosis ofd-IBS: (i) abnormal stool frequency, e.g., greater than 3 times per day;(ii) abnormal stool form, e.g., loose/watery stool; (iii) presence ofurgency (having to rush to have a bowel movement).

Definitions

Unless otherwise defined, all terms of art, notations and otherscientific terms or terminology used herein are intended to have themeanings commonly understood by those of skill in the art to which thisinvention pertains. In some cases, terms with commonly understoodmeanings are defined herein for clarity and/or for ready reference, andthe inclusion of such definitions herein should not necessarily beconstrued to represent a substantial difference over what is generallyunderstood in the art. The practice of the present invention willemploy, unless otherwise indicated, conventional techniques of molecularbiology (including recombinant techniques), microbiology, cell biology,biochemistry, nucleic acid chemistry, and immunology, which are withinthe skill of the art. Such techniques are explained fully in theliterature, such as, Current Protocols in Immunology (J. E. Coligan etal., eds., 1999, including supplements through 2001); Current Protocolsin Molecular Biology (F. M. Ausubel et al., eds., 1987, includingsupplements through 2001); Molecular Cloning: A Laboratory Manual, thirdedition (Sambrook and Russel, 2001); PCR: The Polymerase Chain Reaction,(Mullis et al., eds., 1994); The Immunoassay Handbook (D. Wild, ed.,Stockton Press NY, 1994); Bioconjugate Techniques (Greg T. Hermanson,ed., Academic Press, 1996); Methods of Immunological Analysis (R.Masseyeff, W. H. Albert, and N. A. Staines, eds., Weinheim: VCH Verlagsgesellschaft mbH, 1993), Harlow and Lane Using Antibodies: A LaboratoryManual Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.,1999; and Beaucage et al. eds., Current Protocols in Nucleic AcidChemistry John Wiley & Sons, Inc., New York, 2000).

As used herein, the term “derivative” in the context of polypeptides orproteins refers to a polypeptide or protein that comprises an amino acidsequence which has been altered by the introduction of amino acidresidue substitutions, deletions or additions. The term “derivative” asused herein also refers to a polypeptide or protein which has beenmodified, i.e., by the covalent attachment of any type of molecule tothe polypeptide or protein. For example, but not by way of limitation,an antibody may be modified, e.g., by glycosylation, acetylation,pegylation, phosphorylation, amidation, derivatization by knownprotecting/blocking groups, proteolytic cleavage, linkage to a cellularligand or other protein, etc. A derivative polypeptide or protein may beproduced by chemical modifications using techniques known to those ofskill in the art, including, but not limited to specific chemicalcleavage, acetylation, formylation, metabolic synthesis of tunicamycin,etc. Further, a derivative polypeptide or protein derivative possessesat least one similar or identical biological function as the polypeptideor protein from which it was derived.

As used herein, the term “derivative” in the context of anon-proteinaceous derivative refers to a second organic or inorganicmolecule that is formed based upon the structure of a first organic orinorganic molecule. A derivative of an organic molecule includes, but isnot limited to, a molecule modified, e.g., by the addition or deletionof a hydroxyl, methyl, ethyl, carboxyl, amine group, esterification,alkylation or phosphorylation, immobilization or addition of a polymer.

As used herein, the term “polymer” refers to compounds comprising threeor more monomeric units which may be the same or different. Thus,“polymer” refers to high molecular weight and/or insoluble polymers aswell as low molecular weight and/or soluble oligomers.

As used herein, the term “fragment” refers to a peptide or polypeptidecomprising an amino acid sequence of at least 5 contiguous amino acidresidues. In one embodiment, a fragment of a polypeptide retains atleast one function of the polypeptide.

As used herein, the term “inhibiting CFTR function” refers to inhibitingany function of a CFTR molecule by any means including, but not limitedto, inhibiting chloride ion transport, and inhibiting expression of theCFTR molecule.

As used herein, the terms “nucleic acids” and “nucleotide sequences”include DNA molecules (e.g., cDNA or genomic DNA), RNA molecules (e.g.,mRNA), combinations of DNA and RNA molecules or hybrid DNA/RNAmolecules, and analogs of DNA or RNA molecules.

As used herein, the terms “subject” and “patient” are usedinterchangeably. As used herein, the terms “subject” and “subjects”refer to an animal, preferably a mammal including a non-primate (e.g., acow, pig, horse, cat, dog, rat, and mouse) and a primate (e.g., amonkey, such as a cynomolgous monkey, and a human), and more preferablya human. In a preferred embodiment, the subject is a human. In a oneembodiment, the term “subject” excludes those subjects who suffer fromor have been diagnosed with secretory (acute) diarrhea.

As used herein, the terms “treat”, “treatment” and “treating” refer tothe prevention, reduction, amelioration or elimination of a symptom orcomplication of d-IBS. The term “prevention, reduction, amelioration orelimination of a symptom of d-IBS” in the context of the presentinvention refers to at least one of the following: prevention of d-IBSbefore it occurs, for example, in patients that suffered in the pastfrom d-IBS but are now in a period of remission; elimination ofestablished d-IBS (as determined by, for example, the return of normalstool frequency); elimination of pain associated with d-IBS; reductionof an undesired symptom of the disease as manifested by a decrease inthe severity of an existing condition of d-IBS; elimination or reductionof one or more medications used in treating the subject. The reductionin the undesired symptom may be determined by, for example, measuringstool frequency, determining stool consistency, determining the presenceof urgency, determining pain associated with d-IBS as compared to beforetreatment. Any amount of reduction in the severity of a symptom, even ifsome of the symptom remains at a lower, more acceptable level(“management”), is encompassed by the term herein defined. Suchremediation may be evident as a reduction in stool frequency, increasein stool consistency, lessening of the presence of urgency, lessening ofpain.

Since d-IBS is always accompanied by other non diarrhea-relatedsymptoms, such as abdominal discomfort, pain, bloating, fatigue, sleepdisturbances, sexual dysfunction, headache, fibromyalgia (muscleaching), dyspepsia (upper abdominal discomfort or pain), chest pain,urinary or gynecological symptoms, anxiety and depression. Reduction inat least one of these symptoms is also encompassed by the term“prevention reduction, management or elimination of a symptom orcomplication of d-IBS.”

As used herein, the term “therapeutically effective amount” refers tothat amount of the therapeutic agent sufficient to result in thetreatment of d-IBS, to prevent advancement of d-IBS, cause regression ofd-IBS, or to enhance or improve the therapeutic effect(s) of anothertherapeutic agent administered to treat or prevent d-IBS.

The following series of Examples are presented for purposes ofillustration and not by way of limitation on the scope of the invention.

EXAMPLES Example 1: Preparation of Pharmaceutical Formulations

Described below are illustrative methods for the manufacture andpackaging for different preferred pharmaceutical formulations of theproanthocyanidin polymer composition from C. lechleri according to thepresent invention.

1A. Encapsulated Enteric Coated Beads

Detailed descriptions of the batch formula and methods used to preparethe encapsulated enteric coated proanthocyanidin polymer compositionbead formulation based on sugar spheres are provided below. Eachhard-shell gelatin capsule contained 250 mg proanthocyanidin polymercomposition enteric coated beads. Capsules were packaged in HDPE bottlescontaining sixteen (16) 250 mg caps each. The formulation for entericcoated proanthocyanidin polymer composition beads contained 17.3% (w/w)of nonpareil seeds (sugar spheres 40/60 mesh, Paulaur, lot #60084060),64.5% proanthocyanidin polymer composition from C. lechleri, 1.5%hydroxypropylmethylcellulose (Methocel E5 Premium, Dow Chemical Co., lot#MM9410162E), 0.5% Opadry Clear (Colorcon, lot #S83563), 14.5%“EUDRAGIT™ L 30D” (Rohm Tech., lot #1250514132), 1.45% triethyl citrate(Morflex, lot #N5X291), glyceryl monostearate (Imwitor-900, Rohm Tech,lot #502-229), and purified water (USP).

The layering coating solution containing the proanthocyanidin polymercomposition was prepared by adding hydroxypropylmethylcellulose and theproanthocyanidin polymer composition to purified water (USP) and mixinguntil dissolved. The nonpareil seeds were loaded into the product bowlof the fluid bed processor (Nior-Precision Coater). The polymer solutionwas then layered on the nonpareil seeds by spraying the solution ontothe fluidized nonpareil seeds at a target bed temperature of 30-35° C.Once the proanthocyanidin polymer layering had been completed, a sealcoat using Opadry Clear (preparing by mixing the Opadry Clear withPurified Water, USP) was applied with a target bed temperature of 30-35°C. After the seal coat was applied, the pellets were discharged andscreened through 1000μ and 425μ screens, and the layered spheres largerthan 425μ and smaller than 1000μ were charged back into the fluid bedprocessor. Meanwhile, the enteric coating solution was prepared bymixing triethyl citrate and glyceryl monostearate to water that had beenheated to 65° C. and then mixing this solution with the “EUDRAGIT™ L30D-55”. The resulting enteric coating solution was then sprayed ontothe layered spheres in the fluidized bed processor, at a bed temperatureof 30-35° C., until all the enteric coating solution was layered on thebeads. Based on the results of the HPLC assay indicating that theproanthocyanidin polymer composition was present at a concentration of52.9%, the enteric coated beads were hand filled into a Size #0 hardshell gelatin capsule to provide a 250 mg dosage and then packaged intoa suitable HDPE bottles with a heat induction lined cap.

TABLE 1 BATCH FORMULA Product: Proanthocyanidin Polymer Enteric CoatedBeads Batch Size: 578.0 gm Raw Material Amount Used Per Batch SugarNonpareil Spheres, NF (40/60) 100.0 gm Proanthocyanidin PolymerComposition 372.8 gm Hydroxypropylmethylcellulose E5, USP 8.7 gm(K29/32) Opadry Clear (YS-1-19025A) 2.9 gm “EUDRAGIT ™ L 30D-55” 279.4gm (30% solids) Triethyl Citrate, NF 8.4 gm Glycerol Monostearate 1.4 gmWater, USP (Removed during processing) 1284.8 gm

1B. Encapsulated Enteric Coated Beads

Described below are the formula and methods used to prepare encapsulatedenteric coated bead formulations that do not contain nonpareil sugarspheres. One formulation contains 83.3% w/w proanthocyanidin polymercomposition, 0.5% w/w Opadry clear, 14.5% w/w “EUDRAGIT™ L 30D-55”, 1.9%w/w triethyl citrate and a 0.34% glyceryl monostearate.

The beads were first seal coated with a 5% solution of Opadry clear in a16 liter aeromatic MP-1 fluidized bed processor with a 50 mm Wurstercolumn. The coating parameters for the application of the seal coatingwere an inlet temperature of 50° C. to 60° C., an outlet temperature of25° C. to 40° C., an air volume of 30 to 40 CMH, a spray rate of 6 to 12grams per minute, and an air pressure of 2.5 Bar. After the seal coatwas applied, the beads were discharged and screened for beads largerthan 425μ and smaller than 1000μ. The beads of appropriate size werethen charged back into the fluid bed processes for enteric coating. Foreach 1000 grams of proanthocyanidin polymer composition beads, anenteric coating suspension was prepared from 811.97 grams “EUDRAGIT™ L30D-55”, 24.36 grams triethyl citrate, 4.36 grams glyceryl monostearateand 248.55 grams purified water. This suspension was prepared by gentlystirring the “EUDRAGIT™ L 30D-55” suspension continually and, in aseparate container, suspending and homogenizing the triethyl citrate andtalc in purified water. The triethyl citrate/talc mixture was then addedto the “EUDRAGIT™ L 30D-55” suspension, and the resulting coatingdispersion stirred during the spraying process to avoid settling. Thebeads were then coated in the fluidized bed processor under thefollowing parameters: The inlet temperature was 42° C. to 47° C.; theoutlet temperature was 28° C. to 34° C.; the air volume was 30-40 CMH;the spray rate was 6-12 grams/minute; and the air pressure was 2.5 Bars.The resulting enteric coated beads were then filled into a size #0 hardshell gelatin capsule.

1C. Enteric Coated Granules and Powder Particles

Described below is a method for formulating the proanthocyanidin polymercomposition as enteric coated granules or powder (microspheres with adiameter of 300-500μ) in either hard shell gelatin capsules or suspendedin an oral solution. The proanthocyanidin polymer composition powderparticles are prepared by high-shear powder mixing of theproanthocyanidin polymer composition and hydroxypropylmethylcellulose ina high speed mixer/granulator. The proanthocyanidin polymer compositiongranules are prepared by spraying polyvinylpyrrolidone on the powder inthe high speed mixer/granulator so that the powder particles agglomerateto form larger granules. Using fluidized bed equipment, the granules orpowder are then covered with a seal coat of Opadry Clear (mixed withwater) and then coated with the enteric coating “EUDRAGIT™ L 30D”applied as an aqueous dispersion containing 30% w/w dry methacrylatepolymer substance, which is supplied with 0.7% sodium lauryl sulfate NF(SLS) and 2.3% polysorbate 80 NF (Tween™ 20) as emulsifiers, to whichthe plasticizers, triethyl citrate and glyceryl monostearate, are addedto improve the elasticity of the coating. The final composition of theenteric coated powder is 81.8% w/w proanthocyanidin polymer composition,1.5% w/w hydroxypropylmethylcellulose, 0.5% w/w Opadry clear, 14.5% w/w“EUDRAGIT™ L 30D”, 1.45% w/w triethyl citrate, and 0.25% w/w glycerylmonostearate. The final composition of the enteric coated granules is81.8% w/w proanthocyanidin polymer composition, 10%polyvinylpyrrolidone, 1.5% w/w hydroxypropylmethylcellulose, 0.5% w/wOpadry clear, 14.5% w/w “EUDRAGIT™ L 30D”, 1.45% w/w triethyl citrate,and 0.25% w/w glyceryl monostearate.

The enteric coated proanthocyanidin polymer composition granules orparticles may be filled into a hard shell gelatin capsule in an amountwhich provides a suitable dosage.

The enteric coated proanthocyanidin polymer composition granules orpowder particles can also be suspended in a solution for oraladministration, particularly for pediatric administration. Thesuspension solution is prepared by wetting 2 gramshydroxypropylmethylcellulose in 97.8 ml distilled water and 0.2 gramsTween™ 80; mixing this preparation to homogeneity by sonicating, heatingthe solution to 40° C. and stirring for three hours; and then adding theenteric coated proanthocyanidin polymer composition powder particles orgranules to the homogeneous solution.

1D. Enteric Coated Compressed Tablets

A method for formulating the proanthocyanidin polymer composition with adiluent as enteric coated tablets is described below. For each 350 mgtablet, 250 mg proanthocyanidin polymer composition is granulated with 7mg crosslinked sodium carboxymethylcellulose (“AC-DI-SOL™”) and asufficient mass of microcrystalline cellulose (“AVICEL™ PH 200/300”) tobring the total mass to 350 mg. These ingredients are mixed for 20 to 30minutes in a V blender. After the 20 to 30 minutes of mixing, 1.75 mgmagnesium stearate is added and the mixture is blended for an additional4 to 5 minutes. The resulting granules are compressed on a rotary tabletpress using 5/16th inch standard concave punches. The tablets are coatedwith an enteric coating mixture prepared from 250 grams “EUDRAGIT™ L 30D-55”, 7.5 grams triethyl citrate, 37.5 grams talc and 205 grams water.The tablets are then placed in a perforated pan coater (e.g. the“ACCELA-COTA™” system) and rotated at 15 rpm at 40° C. The entericcoating formulation is sprayed using the following conditions: inlet airtemperature of 44° C.-48° C., exhaust air temperature of 29° C.-32° C.,product temperature of 26° C.-30° C., a 1 mm spray nozzle, a pan speedof 30 to 32 rpm, an airflow of 30-32 CFM, and a spray pressure of 20PSI. The tablets are finally cured for 30 minutes as the pan is rotatingat 15 rpm with an inlet air temperature of 60° C. and then, aftershutting off the heat, the tablets are rotated at 15 rpm until thetablets have cooled to room temperature.

1E. Enteric Coated Directly Compressed Tablets

A method for formulating the proanthocyanidin polymer compositionwithout a diluent as enteric coated tablets was carried out as describedbelow. Directly compressible proanthocyanidin polymer composition wasproduced according to the method described in Example 1F, infra. 125 mgtablets were prepared by blending 99.6% w/w directly compressibleproanthocyanidin polymer composition with 0.40% w/w magnesium stearatefor two minutes and then directly compressing the material into 125 mgtablets on a rotary press using ¼ inch diameter round standard concavepunches to a tablet hardness of 4-10 Kp.

The core tablets were tested and found to have an average hardness(n=10) of 4-10 Kp, friability (n=20) of less than 0.7%, an average tableweight (n=10) of 125 mg±7 mg, an average thickness (n=10) of 3.9 to 4.1mm, and a disintegration time (n=6) of not more than 20 minutes.

The coating dispersion was prepared by mixing, per 100 grams of tablets,22.22 grams of a 30% w/w “EUDRAGIT™ L 30D-55” suspension, kept gentlystirred with a mixture of 0.67 grams triethyl citrate, 1.67 grams talcand 20.44 grams purified water which had been mixed until homogeneous.The coating dispersion was continually stirred to avoid settling.

The tablets (in batches of 100,000) were coated with the coatingdispersion in a Compu-Lab 24 inch/30 L pan. The tablets were jogged inthe pan at a speed of 3-5 rpm and pre-warmed to a temperature of 35° C.to 40° C. The tablets were then coated with the enteric coatingdispersion to a 6% to 8% weight gain with the following parameters: aninlet temperature of 45° C. to 65° C.; an exhaust air temperature of 27°C. to 34° C.; a product temperature of 28° C. to 32° C.; a pan speed of8-14 rpm; an air flow of 180 to 240 CHM; an air spray pressure of 10-20psi (pounds per square inch); an initial spray rate of 3 to 4grams/min/kg; and a final spray rate of 4 to 8 grams/min/kg. The tabletswere then cured for 30 minutes in the pan with an inlet temperature of45° C. to 50° C. and a pan speed of 3 to 5 rpm. Finally, the tabletswere allowed to cool to room temperature in the pan at a pan speed of 3to 5 rpm. Four of the 125 mg tablets were then filled into a size zero,opaque Swedish orange-colored gelatin capsule.

The enteric coated proanthocyanidin polymer composition tablets weretested for content uniformity, drug release, microbiological tests andstability, and some analytical in process tests were also performed. Instability studies, the proanthocyanidin polymer composition remainedstable after six months of storage at room temperature as well as underaccelerated temperature and humidity conditions. Finally, the coretablets were tested and found to have an average hardness (n=10) of 4-10Kp, friability (n=20) of less than 0.7%, an average tablet weight (n=10)of 125 mg±7 mg, an average thickness (n=10) of 3.9 to 4.1 mm, and adisintegration time (n=6) of not more than 20 minutes.

1F. Enteric Coated Directly Compressed Tablets

Formulation of the proanthocyanidin polymer composition, without adiluent, as enteric coated tablets was carried out as described below.The directly compressible proanthocyanidin polymer composition wasisolated as described in Example 2, infra. The core tablets wereprepared by milling 250 mg proanthocyanidin polymer composition pertablet (approximately 16 kg total) in a Quadro Comil with an 024R (30mesh) screen and then blending the milled composition in a PattersonKelley 2 cubic foot twin shell blender. 1 mg magnesium stearate(Spectrum Quality Products, Inc., New Brunswick, N.J.) per tablet wasthen added to the composition in the blender and blended for 2 minutes.The blend was then compressed into 251 mg tablets (containing 250 mgproanthocyanidin polymer composition) on a rotary tablet press to atablet hardness of 8-15 Kp and friability less than 0.5%.

The coating dispersion was prepared by first mixing in a first containerthe 25 g (7.5 g solids) “EUDRAGIT™ L 30 D-55” (Huls America, Inc.,Somerset, N.J.) (weight given per 115 grams coated tablets) dispersion.The pigment dispersion was prepared by adding sequentially with constantstirring in a second container 39.59 g purified water, 3.30 grams talc(Alphafil™ 500) (Whittaker, Clark & Daniels, Inc., South Plainfield,N.J.), 6.06 g (3.15 g solids) White Dispersion (pigment)(Warner-Jenkinson, Inc., St. Louis, Mo.), and then 1.05 g triethylcitrate (Morflex, Inc., Greensboro, N.C.). The mixture was thenhomogenized for 15 minutes or until homogenous. While slowly stirring,the pigment dispersion was added to the “EUDRAGIT™ L 30 D-55” dispersionand then stirred for 30 minutes before spraying. Stirring was alsomaintained during the spraying process to avoid settling.

The tablets were coated in batches of 50,000 in a Compu-Lab 24 inch/30 Lpan with the following settings: 10-20 psi atomizing air pressure; 35°C.-60° C. pan inlet air temperature; 5 to 6 inches nozzle tip to tabletbed distance; and 4/2 baffles/nozzles. After adding the tablets to thepan, the pan was jogged at a speed of 3 to 5 rpm and heated to 40° C.The tablets were then sprayed to a weight gain of 11 to 13% with thefollowing parameters: 27°-33° C. target exhaust temperature (to beachieved within ten minutes of spraying); pan speed of 8 to 12 rpm;180-240 CFM air flow; and a spray rate of 2-5 g/min/kg. After achievingthe desired weight gain, the heat was shut off and the pan jogged at 3-5rpm until the tablets were cooled to below 30° C.

The tablets were encapsulated in size AA opaque Swedish orange coloredDB gelatin capsules (Capsugel, Greenwood, S.C.).

500 mg tablets were also produced as described above, except thatcoating was done on batches of 25,000 tablets to a weight gain of 8 to10%.

Example 2: Isolation of Directly Compressible Proanthocyanidin PolymerComposition

A directly compressible proanthocyanidin polymer composition (used toprepare the formulations in Examples 1E and 1F above) was isolated fromthe latex of the Croton lechleri plant as follows:

460 liters of Croton lechleri latex was mixed with 940 liters purifiedwater for ten minutes and then allowed to stand overnight (12 hours) at4° C. The red supernatant was pumped into a holding tank and the residuediscarded. The supernatant was then extracted with 200 liters n-butanolby mixing for ten minutes and then allowing the phases to separate. Then-butanol phase was discarded, and the aqueous phase was extracted twomore times with 200 liters n-butanol each time. After extraction, theaqueous phase was concentrated by ultrafiltration using a 1 kD cut-offmembrane (a low protein binding cellulose membrane), and then theretentate was dried in a tray dryer at approximately 37° C. (±2° C.).

For purification by column chromatography, 6 kg of the dried extract wasdissolved in 75 liters of purified water and stirred for 90 minutes. Thedissolved material was chromatographed on a two column chromatographysystem consisting of a 35 liter CM-Sepharose column (a weak cationexchange resin) and a 70 liter LH-20 column (a size-exclusion resin)connected in series. The material was loaded onto the CM-Sepharosecolumn, washed with 140 liters purified water, and then eluted onto theLH-20 column with 375 liters of 30% acetone. At this point, the twocolumns were disconnected, and the proanthocyanidin polymer compositionwas eluted from the LH-20 column with 250 liters of 45% liters acetone.Fractions were collected into 10 liter bottles and monitored with a UVdetector at 460 nm. Fractions containing material having detectableabsorbance at 460 nm were pooled and concentrated by ultrafiltrationusing a 1 kD cut-off membrane (a low protein binding cellulosemembrane). The retentate was dried using a rotary evaporator in awaterbath at approximately 37° C. (±2° C.).

The proanthocyanidin polymer composition was tested for directcompressibility. 250 mg portions of the proanthocyanidin polymercomposition, in the absence of any binders or excipients, was placedinto a tableting machine and then pressed into tablets of varyingthicknesses (i.e., the greater the pressure on the composition to formit into a tablet, the thinner the resulting tablet). The hardness of thetablets was then determined in a conventional hardness tester. Thefriability of tablets having a hardness of 8-15 kp was determined asdescribed in USP 23 <1216>. The friability was less than 0.5% loss inweight.

Example 3: Components, Composition, and Manufacturing of a Drug Product

3A. Drug Product

The drug product, crofelemer, consists of an enteric-coated 125 mgtablet(s) over-encapsulated in a Size 00, opaque Swedish orange gelatincapsule and backfilled with microcrystalline cellulose. Each capsulecontains 1, 2, or 4 enteric-coated tablets. The tablet core consists of99.93% crofelemer and 0.07% magnesium stearate and is coated with amethacrylic acid copolymer.

3B. Components of Drug Product

Crofelemer is supplied by Napo Pharmaceuticals, Inc., and ismanufactured under current Good Manufacturing Practices (cGMP).Magnesium stearate is manufactured by Mallinckrodt (or equivalent) andmeets the specifications for magnesium stearate as described in 27USP/NF. The magnesium stearate is certified by the manufacturer to bederived from vegetable sources. Microcrystalline cellulose ismanufactured by FMC (or equivalent) and meets the specifications formicrocrystalline cellulose as described in 27 USP/NF. Both high-densityand low-density microcrystalline cellulose are employed. Methacrylicacid copolymer is manufactured by DeGussa under the trade name Eudragit®(L30-D55) and meets the specifications for methacrylic acid copolymer,Type C, as described in 27 USP/NF. Triethyl citrate is manufactured byMorflex (or equivalent) and meets the specifications for triethylcitrate as described in 27 USP/NF. Talc is manufactured by Whittaker,Clark and Daniels (or equivalent) and meets the specifications for talcas described in 27 USP/NF. Purified water is supplied by the drugproduct manufacturer and meets the specifications for purified water asdescribed in 27 USP/NF. Swedish orange opaque, Size 00, hard gelatincapsule bodies and caps are supplied by Capsugel, Inc. (Greenwood,S.C.). The manufacturer certifies that the capsules are made fromgelatins that meet the current National Formulary (NF) requirements forgelatin under cGMP.

3C. Composition Of Drug Product

The composition of the tablet cores and the enteric-coated tablets isdescribed in Table 2 and Table 3, respectively. The amount of crofelemerand magnesium stearate is adjusted based on the anhydrous potency of thedrug substance, which corrects for the moisture content of thecrofelemer. The amount of weight gain after coating is approximately10%. The clinical batch size ranges from 100,000 to 150,000enteric-coated tablets. Subsequently, 1, 2, or 4 enteric-coated tabletsare placed in a Size 00 capsule and backfilled with microcrystallinecellulose to match weights of each capsule strength and placebo.

TABLE 2 Composition of Drug Product 125 mg Tablet Cores TheoreticalQuantitative mg/unit Ingredient Grade Purpose Compositio dose CrofelemercGMP Active 99.93%    125 mg Magnesium 27 USP/NF Lubricant 0.07%  0.13mg stearate Total  100% 125.13 mg

TABLE 3 Composition of Drug Product Enteric-Coated 125 mg TabletsTheoretical Quantitative mg/unit Ingredient Grade Purpose Compositiodose Crofelemer cGMP Active 90.0%  125.13 mg tablet Eudragit 27 USP/NFCoating 7.4% 34.5 mg (10.4 L-30 D55 mg solids) Triethyl 27 USP/NFPlasticizer 0.8%  1.05 mg citrate Talc 27 USP/NF Dispersing 1.8%  2.6 mgPurified 27 USP/NF Solvent N/A*  21.9 mg water* Total 100%  136.4 mg*Purified water is removed during process.

3D. Method of Manufacturing the Drug Product

I. Manufacture of Tablet Core

A sufficient amount of crofelemer and magnesium stearate, based on thepotency of crofelemer, on an anhydrous basis that adjusts for the amountof moisture, is staged prior to manufacture. Crofelemer is added to theblender and magnesium stearate is screened and added to the crofelemer.The crofelemer and magnesium stearate are blended, a representativeblend sample is taken, and the yield is determined. Yield must bebetween 100±3%. Blend uniformity is not determined, except as needed,because the blend is 99.9% active. The blend is directly compressed on arotary tablet press, using 1/a inch round concave punches. Finishedtablet cores are de-dusted and placed in a container to await coating.Prior to the start of the manufacturing run, pre-production runs areperformed to adjust the speed and compression of the press in order tomeet the targeted tablet-core weight, thickness, and hardness. Inaddition, friability and disintegration are measured. During themanufacturing run, tablet-core samples are taken at periodic intervalsto ensure that the tablets continue to meet the targeted tablet weight,thickness, and hardness. Representative tablet cores are taken duringthe beginning, middle, and end of the production run for additionaltesting for hardness, thickness, weight, friability, and disintegration.The average tablet-core weight must be within ±5% of the targetedtablet-core weight. The number of tablet cores, sample tablet cores,tablet-core waste, and blend waste are reconciled and the percentaccountability calculated. The percent accountability must not be lessthan 95% and not more than 103%. A schematic of the tablet coremanufacturing process is illustrated in FIG. 8

II. Coating of Tablet Core

The amount of Eudragit®, triethyl citrate, talc, and purified water iscalculated and staged based on a nominal tablet-core weight gain of 10%.Purified water is charged into a suitable container equipped with ahigh-shear mixer. The triethyl citrate and talc are added to thecontainer and mixed until homogenized. In a separate container equippedwith a propeller mixer, the Eudragit® dispersion is charged and mixed.The triethyl citrate and talc dispersion is added to the Eudragit®dispersion and is continuously stirred throughout the spraying process.The pan-coater machine parameters are adjusted as appropriate and thelines are charged with the coating dispersion. The tablet cores arecharged in a coating pan and warmed to 35 to 40° C. while jogging thecoating pan. Once at temperature, the average weight of the tablet coresis recorded and the targeted coated tablet weight is calculated.Subsequently, the tablet cores are sprayed and periodicallyweight-checked until the targeted weight gain is met. The targeted sprayrate (4 to 8 g/min/kg of tablet cores), the targeted exhaust temperature(35 to 40° C.), and inlet temperature are monitored at frequentintervals. The tablets are cured for 30 minutes at 45 to 50° C., andthen cooled. Representative enteric-coated samples are taken fortesting. The average enteric-coated tablet weight must be within ±5% ofthe targeted enteric-coated tablet weight.

The weight of enteric-coated tablets, enteric-coated tablet samples, andtheoretical quantity of enteric-coated tablets are determined and thepercent accountable yield calculated. The percent accountable yield mustnot be less than 95% and not more than 103%. The tablet-corespray-coating process is illustrated in FIG. 9

III. Manufacture of Over-Encapsulated Enteric-Coated Tablets

The enteric-coated tablets and microcrystalline cellulose are stagedseparately for the over-encapsulation of each capsule strength. Theamount of microcrystalline cellulose to be encapsulated is calculated inorder to achieve a nominal 600 to 800 mg capsule weight, dependent uponthe exact dosage form (125 mg, 250 mg, or 500 mg). The average weight ofthe capsules is calculated based on an average of 100 capsules. Thecapsules are filled using a semi-automatic over-encapsulation machinefitted with Size 00 change parts and adjusted to deliver the properamount of tablets and microcrystalline cellulose. Pre-production runsare performed in order to adjust the tray fill weight, the number ofturns on the tamper, and the number of times tamped in order to meet thetargeted gross capsule weight (capsule shell plus tablets andmicrocrystalline cellulose). Each tray is prepared by placing thecapsule bodies in the capsule tray. Each capsule body is filled with thetargeted amount of tablets and microcrystalline cellulose to achieve thetargeted fill. The caps are placed on the bodies and closed. Thecapsules are removed from the tray and de-dusted. A composite ofcapsules from each tray is collected and weighed for in-process andrelease testing. The average capsule weight is within ±5% of thetargeted capsule weight. The process is then repeated until the desirednumber of capsules is filled. Damaged capsules, enteric-coated tabletwaste, and microcrystalline cellulose waste are collected for finalproduct reconciliation. A composite of the finished capsules is sent forrelease testing. The number of finished capsules, sample capsules,damaged capsules, and drug substance waste are reconciled and thepercent accountability is calculated. The percent accountability mustnot be less than 95% and not more than 103%. A schematic of theover-encapsulation of the enteric-coated tablets is illustrated in FIG.10

Example 4: Effect of Enterically Coated Proanthocyanidin PolymerComposition on Patients Suffering From Diarrhea Predominant IrritableBowel Syndrome

4A. Treatment

The study was a 16-week, multi-center, Phase 2, randomized,double-blind, placebo controlled study in subjects with diarrheapredominant irritable bowel syndrome (d-IBS). Two-hundred and forty-six(246) subjects, meeting the definition of d-IBS as supported by the RomeII Criteria for the Diagnosis of IBS were randomized into four groups:placebo, 125 mg bid, 250 mg bid, and 500 mg bid. The study consisted ofa 2-week treatment-free screening period, a 12-week blinded treatmentperiod, followed by a 2-week treatment-free follow-up period.

During the 2-week screening period, subjects self-reported dailyinformation about the status of their d-IBS symptoms via a touch-tonetelephone diary. This included information about abdominal pain anddiscomfort, stool frequency, consistency and urgency. If the subjectcontinued to meet the inclusion criteria at the end of the screeningperiod, and the information captured in the diary during the screeningperiod indicated they had active d-IBS [mean daily stool frequency ≥2;pain score ≥1; stool consistency ≥3 (5-point Lickert scale for pain andconsistency)], subjects were randomized into one of four groupsaccording to a computer-generated central randomization schema.

During the 12-week double-blind treatment period, subjects continued torecord daily and weekly assessments via a touch-tone telephone diarysystem as instructed. Subjects were seen every 4 weeks during thetreatment period for study assessment visits at which time they receivedadditional study medication.

During the 2-week treatment-free follow-up period, subjects continued torecord daily and weekly assessments.

Results:

There were no drug-related serious adverse events. Adverse event rateswere similar across all dose groups as shown in Table 4. There were nodrug- or dose-related differences in constipation.

TABLE 4 Summary of Adverse Events¹ 125 mg 250 mg 500 mg Placebo bid bidbid No. Subjects/Group 61 62 59 62 No. Subjects with ≥1 AE 14 12 15 15No of GI AEs 7 10 10 10 GI Event Abdominal distention 0 1 0 1 Abdominalpain 1 2 1 2 Abdominal tenderness 0 0 1 0 Constipation 1 3 2 1 Diarrhea1 2 1 0 Dry mouth 0 0 0 2 Eructation 0 0 0 1 Flatulence 1 1 3 1Haematochezia 0 0 1 0 Hemorrhoids 0 1 0 0 Nausea 3 0 1 1 Urgency 0 0 0 1No. of Other AEs 11 12 15 14 Other Events (>1 AE/group) Dizziness 1 0 30 Headache 2 2 1 3 Anxiety 2 0 0 1 Insomnia 0 0 2 1 Rash 1 2 0 0¹possible, probably, or likely related.

In general, crofelemer 125 mg bid, as shown in Table 5 exhibited aconsistent response among most efficacy endpoints in females. Thereappeared to be little efficacy in males; however, group size was toosmall (13-16/group) to analyze separately. Since crofelemer produced noconstipation, stool consistency scores approached normal and were notdifferent from placebo. In all other endpoints (frequency, urgency,adequate relief, and pain), there was an improvement in activity witheach successive month and during the 2 week treatment-free follow-upperiod symptoms began approaching baseline levels as expected.Crofelemer 500 mg bid also had a statistically significant effect onpain (0.48 decrease in pain score; 22.44% increase in pain free days).There were 5 female disease outliers (they had >9 stools/day at baselineand were >3 standard deviations from the mean stool frequency of allrandomized female subjects) that were not representative of the d-IBSpopulation used in this study and were removed from all analysespresented in this summary.

As shown in Table 6, crofelemer at 250 mg and 500 mg bid had less of aneffect on frequency and consistency than the placebo group. Subjectstreated with crofelemer 500 mg bid had a greater than half of stool perday mean increase in stool frequency as compared to placebo; there meanstool consistency was 0.22 points higher (closer to loose consistency)as compared to placebo.

TABLE 5 Efficacy of Crofelemer 125 mg bid in Females Endpoint (Δ fromPlacebo) Results¹ Consistency Score −0.03  Frequency (stools/day) −0.7 Urgency Free Days 11.2% Pain score −0.42* Pain Free Days 12.76%*Adequate Relief   16% ¹Month 3 results; observed case analysis withdisease outliers (mean baseline frequency >9 stools/day) removed fromall groups. *statistically significant at p < 0.05

TABLE 6 The Effects of Crofelemer 250 and 500 mg bid on stoolconsistency and frequency Endpoint (Δ from Placebo) 250 mg bid¹ 500 mgbid¹ Consistency Score 0.19 0.22 Frequency (stools/day) 0.24 0.60 ¹Month3 results; observed case analysis with disease outliers (mean baselinefrequency >9 stools/day) removed from all groups.

As seen in FIG. 4, female subjects treated with crofelemer 125 mg bidhad a clinically significant decrease in stool frequency. Use ofcrofelemer led to a decrease of greater than one bowel movement per day.The month-to-month improvement in stool frequency was contrasted by theplacebo effect diminishing at month two as values began to approachbaseline. When the treatment-free period began at the end of monththree, the subjects stopped taking crofelemer and the effect began to goaway as expected.

As seen in FIG. 5, crofelemer produced an increase in urgency free days.At Month 3, there was a 35.1% increase in urgency free days in thecrofelemer group versus a 23.9% increase in urgency free days observedin the placebo group. There was a month-to-month improvement, ascommonly seen. The placebo effect peaked at month two and abruptlydecreased as values begin to approach baseline. When the treatment-freeperiod began at the end of month three, the subjects stopped takingcrofelemer and the effect began to go away as expected.

As seen in FIG. 6, administration of crofelemer produced an increase inthe percentage of subjects reporting adequate relief of d-IBS symptoms.Since d-IBS is comprised of a group of symptoms, the adequate reliefendpoint is an overall assessment by the patient as to how well thetreatment is addressing their d-IBS symptoms. Crofelemer at 125 mg bidcaused a 16% increase in the adequate relief of d-IBS symptoms ascompared to the placebo group. With the observed analysis, there was amonth-to-month improvement in activity of crofelemer, i.e., the longerthe patient took crofelemer, the greater relief of symptoms. Aspreviously seen with other endpoints, the placebo effect peaked at monthtwo and decreased thereafter.

Diarrhea-predominant IBS is differentiated from many functional boweldiseases by the close association of pain with changes in bowel habits.As defined by the Rome II Criteria for the Diagnosis of IBS, pain mustbe associated with abnormal bowel habits and the improvement of thebowel habits should be associated with the improvement of pain. In thisstudy we have measured pain score with a 5-point scale, where 0 is noneand 5 is severe; and the presence of pain free days. As shown in FIG. 4and FIG. 5, female subjects treated with crofelemer (125 and 500 mg bid)had clinically and statistically significant (p<0.05) decreases in bothpain score and pain free days. The effect is quite consistent asobserved in the weekly pain score results shown in FIG. 6. This effecton pain relief was unexpected and surprising.

In conclusion, crofelemer at 125 mg bid, was safe and its administrationresulted in improvement in the efficacy endpoints of pain, adequaterelief, frequency, and urgency in female subjects. Crofelemer at 250 and500 mg bid was safe and, compared to placebo, appeared to worsen thediarrheal symptoms of consistency and frequency. Crofelemer at 125 and500 mg bid produced a statistically significant decrease in both painscore and pain free days in female subjects with d-IBS.

Example 5: Investigation of Crofelemer Mechanism of Action

To further investigate the mechanism of action of crofelemer, crofelemerat 10 and 100 g/mL was evaluated in a selected panel of cellularcytokine release assays (IL-1α; TNF-α-induced and IL-1-induced PGE2release; IFN-γ; IL-2, IL-4; IL-5; IL-6; IL-8; IL-10 and TNF-α) andmolecular assays (COX-1 and COX-2 enzyme assays, and glucocorticoid,serotonin 5HT3, δ-opiod, κ-opiond, μ-opiod, and non-selective opiodreceptor binding assays. Crofelemer was also tested in cytotoxicityassays corresponding to the ConA- and LPS-induced cytokine releaseassays as well as those corresponding to the TNF-α- and IL-1-induced PGErelease assays.

Crofelemer exhibited significant (>50%) inhibition in the IFN-γ; IL-2,IL-4; IL-6; IL-8; IL-10 and TNF-α cytokine release assays as well as inthe TNF-α-induced and IL-1-induced PGE2 release assays at 10 and 100μg/mL (i.e., all cytokine release assays with the exception of IL-5).Crofelemer also displayed significant cytotoxic activity in the ConA andIL-1-induced PGE2 cytotoxicity assays suggesting that in theConA-mediated cytokine release assays (IFN-γ, IL-2, IL-4 and IL-10) andthe IL-1-induced PGE2 release assay may be due to general cytotoxicity.

Further, at both 10 and 100 μg/mL, crofelemer caused a 73% and 100%inhibition in the COX1 and COX2 enzyme assays, respectively.

Many modifications and variations of this invention can be made withoutdeparting from its spirit and scope, as will be apparent to thoseskilled in the art. The specific embodiments described herein areoffered by way of example only, and the invention is to be limited onlyby the terms of the appended claims, along with the full scope ofequivalents to which such claims are entitled. Such modifications areintended to fall within the scope of the appended claims.

All references, patent and non-patent, cited herein are incorporatedherein by reference in their entireties and for all purposes to the sameextent as if each individual publication or patent or patent applicationwas specifically and individually indicated to be incorporated byreference in its entirety for all purposes.

What is claimed is:
 1. A method of treating a patient having painassociated with diarrhea-predominant irritable bowel syndrome (d-IBS),comprising administering to the patient a composition comprising aproanthocyanidin polymer derived from C. lechleri in an amountbioequivalent to crofelemer at a dosage of about 100 mg per day to about300 mg per day.
 2. The method of claim 1, wherein the proanthocyanidinpolymer is crofelemer.
 3. The method of claim 1, wherein the compositionis orally administered.
 4. The method of claim 3, wherein theproanthocyanidin polymer is crofelemer.
 5. The method of claim 4,wherein crofelemer is enteric coated.
 6. The method of claim 5, whereincrofelemer is administered to the patient at about 250 mg per day. 7.The method of claim 5, wherein crofelemer is administered to the patientat about 125 mg twice daily.
 8. The method of claim 1, wherein theamount of the proanthocyanidin polymer is bioequivalent to crofelemer ata dosage of about 250 mg per day.
 9. The method of claim 1, wherein theamount of the proanthocyanidin polymer is bioequivalent to crofelemer ata dosage of about 125 mg twice daily.
 10. The method of claim 1, whereinthe number of pain-free days are increased by at least 10% afteradministration of the composition.
 11. The method of claim 1, whereinthe average level of pain as measured by a pain score is decreased afteradministration of the composition.
 12. The method of claim 1, whereinthe number of days free of the urgency for stool passage is increasedafter administration of the composition, wherein said urgency isassociated with d-IBS.
 13. The method of claim 1, wherein the patient isa human female.
 14. The method of claim 1, wherein the composition isadministered twice daily.
 15. A method of treating a patient havingurgency for stool passage associated with diarrhea-predominant irritablebowel syndrome (d-IBS), comprising orally administering to the patient acomposition comprising enterically coated crofelemer in an amounteffective to reduce urgency for stool passage associated with d-IBS,wherein crofelemer is administered to the patient at about 200 mg perday to about 300 mg per day.
 16. The method of claim 15, wherein thedaily stool frequency is also decreased after administration of thecomposition.
 17. The method of claim 15, wherein the crofelemer isadministered to the patient at about 125 mg twice a day.
 18. The methodof claim 15, wherein the composition is administered twice daily.